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IL-10 and TGF- are immunosuppressive cytokines found in tumors including melanoma 
and, therefore, deemed as the major cause for failing anti-tumor immune responses. However, 
conflicting evidence reported IL-10 and TGF--mediated immune stimulation urges a re-
evaluation of their role in tumors. To clarify this discrepancy in melanoma, their expression 
was compared by quantitative RT-PCR in melanoma and the skin of healthy individuals. 
Furthermore, their induction in co-cultures of dendritic and T cells with tumor cells and their 
effects on immune cells were tested. Both, as well as their receptors were expressed in 
melanoma but at significantly lower levels than in healthy skin. Consequently, the expressions 
of SOCS-3 and SMAD-7 as responsive genes of IL-10 and TGF- respectively were low in 
tumors but high in healthy skin. T cells co-cultured with a large number of tumor cells 
developed an anergic state but without a correlation with IL-10 or TGF-production. In 
addition, the anergic state of T cells induced in vitro was reversed to a certain extent when a 
high concentration of exogenous IL-10 or TGF- was added. A combination of IL-10 and 
TGF- gave a better result than using either cytokine alone. However, a high concentration of 
IL-10 could suppress functional T cells, supporting the idea that IL-10 acts differently at 
different activation and functional stages of T cells. iDCs differentiated in the presence of 
tumor cells in vitro had a mix population of complete and incomplete differentiated iDCs, 
produced a high IL-10 level and were less efficient in inducing T cell proliferation. However, 
they could be induced to mature, and blocking IL-10 did not alter the capacity of the resulting 
mature DCs to induce CD4 T cell proliferation. Increased TGF- production could only be 
seen when DCs were generated in direct contact with a large number of tumor cells. Blocking 
TGF- during the differentiation of iDCs in the presence of tumor cells did not change the DC 
phenotype and capacity to induce CD4 T cell proliferation. These results indicate that both 
cytokines did not alter the capacity of DCs to induce CD4 T cell proliferation. DCs induced 
into maturation in the presence of tumor cells produced increased IL-10, in opposite to   
similar or even decreased TGF- levels and were more efficient in inducing T cell 
proliferation. The lack of correlation of IL-10 and TGF- with immune deficits in situ and in 
vitro suggests reconsidering their role in cancer.  
  





IL-10 und TGF-ß sind immunsupprimierende Zytokine, die in verschiedenen Tumoren, u.a. 
im Melanom, entdeckt wurden und als Hauptursache für das Versagen der Anti-
Tumorimmunantwort angesehen werden. Allerdings wurden divergente Daten auch berichtet. 
Um diese Diskrepanz zu erklären, wurde die Expression dieser Zytokine mittels quantitativer 
RT-PCR im Melanom und in Haut gesunder Individuen verglichen. Weiterhin wurde die 
Induktion beider Zytokine in Kokulturexperimenten mit Dendritische Zellen und T-Zellen 
zusammen mit Tumorzellen sowie ihr Einfluß auf das Immunsystem untersucht. Beide 
Zytokine sowie deren Rezeptoren wurden im Melanom exprimiert, aber im Vergleich mit 
gesunder Haut auf signifikant geringerem Level. Dementsprechend waren die Expressionen 
von IL-10-induzierbare-SOCS-3 und auch TGF--induzierbare-SMAD-7 im Tumor gering 
und in der gesunden Haut hoch. T-Zellen, die mit einer großen Zahl an Tumorzellen 
kokultiviert wurden, entwickelten einen anergischen Zustand, aber ohne mit dem IL-10 oder 
TGF-ß Level zu korrelieren. Dieser in-vitro-induzierte anergische Zustand der T-Zellen wurde 
durch Zugabe hoher Konzentrationen an exogenem IL-10 oder TGF-ß  zu einem gewissen 
Grad wieder aufgehoben. Eine Kombination von IL-10 und TGF-ß resultierte in einem 
deutlicheren Ergebnis als die Verwendung eines Zytokins alleine. Allerdings konnte eine 
hohe Konzentration an IL-10 funktionelle T-Zellen unterdrücken, was die Idee unterstützt, 
dass IL-10 in verschiedenen Aktivierungs- und funktionellen Stadien der T-Zellen 
unterschiedlich wirkt. Dendritische Zellen, die zusammen mit Tumorzellen kokultiviert 
wurden, wiesen eine gemischte Population an vollständig und unvollständig differenzierten 
iDCs auf, produzierten hohe Level IL-10 und konnten die CD4 T-Zellproliferation weniger 
effizient induzieren. Trotzdem konnten sie zur Reifung induziert werden, wobei die 
Blockierung von IL-10 nicht die Fähigkeit der resultierenden, reifen DCs veränderte, CD4 T-
Zellproliferation zu induzieren. Die erhöhte Produktion an TGF-ß wurde ausschließlich 
beobachtet, wenn DCs durch direkten Kontakt mit einer großen Zahl an Tumorzellen 
generiert wurden. Die Blockierung von TGF-ß während der Differenzierung der 
tumorassoziierten iDCs veränderte nicht den DC-Phänotyp und die Fähigkeit, CD4 T-
Zellproliferation zu induzieren. Diese Ergebnisse zeigen, dass beide Zytokine die Funktion 
der DCs nicht verändern. DCs, deren Reifung in der Gegenwart von Tumorzellen induziert 
wurde, produzierten erhöhte Level an IL-10, dagegen gleiche oder verminderte Level an 
TGF-ß und waren effizienter in der Induktion der CD4 T-Zellproliferation. Die fehlende 
Korrelation von IL-10 und TGF-ß mit den Immundefiziten in situ und in vitro legt den Schluß 
nahe, ihre Rolle bei Krebs neu zu überdenken.   






Melanoma is a cancer arisen from melanocytes found predominantly in the skin. It is a 
very aggressive type of cancer and the mortality rate is the highest among skin cancer related 
deaths. In the early stages, melanoma can be cured by surgery but at advanced stages, patients 
show poor responses to therapy (reviewed in Kuphal and Bosserhoff, 2009).  
The American Joint Committee on Cancer (AJCC) classification system is based on 
principal that malignant tumor follows the timely progression. The current AJCC system for 
cutaneous melanoma classifies patients into primary tumor (T1-4), regional lymph nodes (N1-
3), and distant metastasis (M1-3). Besides the TNM staging, anatomic staging group is also 
used for classifying melanoma into 4 stages. Stages I and II are localized melanoma, stage III 
is regional metastatic melanoma and stage IV is distant metastatic melanoma (Kim et al, 
2002; Balch et al, 2009). 
Several risk factors are linked to the development of melanoma, such as gene 
mutation, chronic immunosuppression and environmental exposure. Several susceptible genes 
have been implicated to play a role in the pathogenesis of melanoma. BRAF mutation is the 
most frequent mutation found in melanoma. Mutations in the BRAF oncogene leads to 
constitutive activation of mitogen-activated protein kinase (MAPK) signaling pathway, 
inducing cell proliferation. Mutation of BRAF is reported to promote tumorigenicity in nude 
mice (Davies et al, 2002; Kumar et al, 2003). CDKN2A tumor-suppressor gene encodes the 
negative regulator of cell proliferation, providing the mechanism of holding cell proliferation 
at the G1/S1 checkpoint to permit repair of DNA damage. Loss of CDKN2A function results 
in the loss of proliferative and apoptotic control (Goldstein et al, 2000). Tumor-suppressor 
gene PTEN (Phosphatase and Tensin Homolog deleted on Chromosome ten) encodes a PTEN 
protein which has a lipid phosphatase and a protein phosphatase activity. The lipid 
phosphatase activity of PTEN arrests the cell cycle progression at G1/S phase, upregulates 
proapoptotic machinery and downregulates the antiapoptotic proteins. The protein 
phosphatase activity involves in the cell spreading and migration, as well as the inhibition of 
MAPK signaling. Therefore, the loss of lipid and protein phosphatase activity of PTEN 
results in the uncontrolled growth of cells, escape from apoptosis, abnormal cell spreading 
and migration (Wu et al, 2003). Familial melanoma syndrome has been associated with 
germline mutation of several gene products: p16, alternate reading frame (ARF) and cyclin-
dependent kinase-4 (CDK4), which are all involve in the cell cycle control (Goldstein et al, 




2000; Pho et al, 2006). Immunosuppression has also been associated with a higher risk of 
melanoma since a higher incidence occurs in patients with acquired immunodeficiency 
syndrome and post-transplant patients receiving immunosuppressive agents (Euvrard et al, 
2003). A short, intense episode of burning sun exposure, as well as cumulative UV exposure 
over the years may contribute to the risk factors of melanoma. UV radiation can induce DNA 
damage. In most cases, cells repair the DNA damage and survive or they undergo apoptosis 
when the damage is irreparable. However melanocytes produce a high level of prosurvival 
factor Bcl2 which could help the mutant melanocytes escape apoptosis from which melanoma 
eventually arises (Gruber et al, 2008, Mackie et al, 2009, Jhappan et al, 2003). 
To date, surgery through wide local excision remains the standard procedure 
(Ingraffea, 2013). However, due to the aggressiveness of the tumor and the limited efficiency 
of currently applied therapeutics such as chemo-and radio-therapy, the survival rate of 
patients with metastatic melanoma is very low. Median survival rates after metastasis occurs 
is 6-9 months, with records of a 5-year survival rate less than 10% (Ingraffea, 2013). A new 
experimental strategy, such as immunotherapy has been offered as an alternative treatment for 
the late stage of melanoma patients, with limited success so far. Immunotherapy for malignant 
melanoma strives to stimulate the patients’ immune system to fight the cancer. Several 
approaches have been applied to treat melanoma, including treatment with cytokines such as 
Interleukin (IL)-2 and Interferon (IFN)-. Treatment of IL-2, the first immunotherapy 
approved by Food and Drug administration (FDA), could only demonstrate a small efficiency 
range from 6-10% with no clinically meaningful prolongation of overall survival. IFN- 
treatment shows a modest antitumor activity but the responses are limited to patients with 
low-volume disease in cutaneous or soft-tissue sites. Furthermore, concern about high toxicity 
regarding the high dosage needed to apply has arisen (Markovic et al, 2007, Bhatia et al, 
2009). 
Another experimental approach is by using a tumor vaccine. A study showed that a 
trivalent vaccine against self-melanoma antigen glycoprotein 100 (gp100), tyrosinase and 
melanoma antigen recognized by T cells 1 (MART-1) demonstrated a promising result in 
increasing T cell activity against melanoma. Nevertheless, treatment with a peptide vaccine is 
a very specific approach. Treatment with signal transduction inhibitor which includes BRAF 
kinase inhibitor or a combination of BRAF and mitogen-activated-ERK (MEK) inhibitor is 
associated with increased CD8 T cells infiltration in melanoma and increased expression of 
melanoma antigens. But again, this treatment is limited to the patients with melanoma 




containing BRAF mutation. Furthermore, the medications targeting mutated BRAF 
(Vemurafenib and GSK2118436) are limited to a short duration due to the emerging 
resistance to therapy and are associated with the increased development of squamous cell 
carcinomas (Frederick et al, 2013, Ingraffea, 2013; Callahan et al, 2013; Finn et al, 2012). 
The limitation of immunotherapy against melanoma is caused mainly by tumor escape 
mechanism. Understanding the biology of melanoma is therefore important to develop new 
therapeutic approaches. 
 
1.2. Tumor immunology 
 The immunosurveillance hypothesis states that the immune system surveys the whole 
body and is able to recognize and eliminate tumor cells. The major key effector cells in 
fighting tumor cells are T cells and the natural killer (NK) cells (reviewed in Igney and 
Krammer, 2002). 
T cells are able to kill tumor cells in an antigen dependent manner. Effective activation 
of naïve T cells requires several signals. The first signal is the interaction between T cell 
receptor (TCR) and MHC (major histocompatibility complex)-peptide complex. The second 
signal is the interaction between co-stimulatory molecules on T cells (i.e., CD28) and antigen 
presenting cells (APC) (i.e., B7-1 and B7-2). The third signal is the cytokines produced by 
dendritic cells (DC) to stimulate T cells. Various tumor antigens can be recognized by T cells. 
Some of these antigens are expressed exclusively by tumor (tumor specific antigens). These 
antigens arise from mutations of normal genes. Some other antigens are shared by tumor cells 
and healthy cells (tumor associated antigens). Overexpressed non-mutated proteins could also 
serve as tumor antigens for T cells. Upon recognition of tumor antigens, CD8 T cells are 
activated and become cytotoxic T cells (CTL), which can kill the target cells. CTL can kill the 
target cells using different mechanisms: perforin/granzyme pathways and Fas-FasL 
interaction. The release of perforin and granzymes leads to perforation of target cells and 
subsequent apoptotic death induced by granzymes. The Fas-FasL interaction also induces 
apoptosis. Besides CD 8 T cells, there is another set of T cells, which is called CD4 T cells. 
Based on the differences of cytokine production pattern in mouse, CD4 T cells are divided 
into CD4 helper T cells type I (TH1) and type II (TH2) subsets. TH1 cells help the activation 
of CTL to kill target cells, while TH2 cells help to stimulate a humoral response and suppress 
the development of the TH1 response. Human CD4 T cells that exhibit TH1 and TH2-like 




phenotype was found in tissue or peripheral blood of patients in different disease states 
(reviwed in Igney and Krammer, 2002; Shresta et al, 1998; Romagnani, 1991). 
 Activation of NK cells depends on the balance of the inhibitory and activating signals.  
Cells expressing reduced inhibitory ligands (e.g. MHC class I molecules) and/or increased 
activating ligands will activate NK cells. The two main groups of inhibitory receptors of NK 
cells in humans are the killer-cell immunoglobulin-like receptors (KIRs) family that sense the 
classical MHC class I expression and the CD94/NKG2A receptors that bind to non-classical 
MHC class I molecule HLA-E. The lack of MHC class I, which sometimes occurs in tumors, 
will activate NK cells. In humans, the major activating receptors are NCR NKp30, NKp44 
and NKp46 and CTLR NKG2D. Upon activation, NK cells release perforin and granzymes. 
NK cells could also kill the target cells by inducing apoptosis mediated by surface TNF ligand 
family members (FasL, TNF- and TRAIL) that interact with specific receptors on the target 
cell surface. In addition, NK cells also secrete cytokines and chemokines, which will help 
effector cells to eliminate target cells (reviewed in Waldhauer and Steinle, 2008; Zamai et al, 
2007).  
 
1.3. Immunesuppressive mechanisms in tumor 
Melanoma is highly immunogenic (able to induce immune response) and often found 
to be heavily infiltrated by immune cells. One offered explanation of the immunogenicity of 
melanoma is due to the presence of melanoma antigen (Melan-A, NY-ESO-1, MART-1, 
gp100, gp75, tyrosinase) (Hussein, 2005). But since the tumor persists and can grow 
progressively in patients, the immune system is clearly ineffective to completely eradicate the 
tumor. Several possibilities have been proposed to explain the failure of the immune response 
to completely eliminate cancer. They can generally be classified into the inhibition of anti-
tumor priming and the inhibition of effector functions (Frey and Monu, 2008).  
In the first category falls the modulation of antigenicity. Tumor cells can escape T cell 
recognition by modulating the presentation or processing of antigens. Downregulation of 
MHC class I as well as class MHC class II molecules in malignant cells has been shown. 
Several mechanisms that alter the MHC molecules in human (called human leukocyte antigen 
(HLA)) are described, such as defect of beta (2)-microglobulin synthesis, loss of genes 
encoding or downregulation of HLA heavy chain, defect of regulatory mechanism that control 
HLA expression, and alteration in antigen processing machinery (reviewed in Campoli and 




Ferone, 2008; Yaguchi et al, 2011). In some tumor cases, expressions of tumor antigens (e.g., 
MART-1, Melan-A) are downregulated. Furthermore, mutations in the antigens can result in 
the escape from tumor recognition by T cells (Igney and Krammer, 2002). 
Another suggested mechanism that limits T cell activation in tumor cases is the lack of 
co-stimulation. B7 co-stimulatory molecules play an important role to activate T cells. The 
failure of co-stimulatiory signaling could lead to an immunological tolerance. 
Immunohistochemistry and FACS analysis show no expression of B7 on primary and 
established head and neck squamous cell cancer (Wollenberg, et al, 1998).   
There is increasing evidence that DCs isolated from cancer patients have functional 
deficiency, thereby decreasing their capacity to induce immune responses. Mature DCs 
express high levels of activation markers and produce high level of cytokines, enable them to 
stimulate T cells to induce immune responses. DCs can be activated via pattern recognition 
receptors (PRRs) or inflammatory cytokines signaling. PRRs are protein expressed by innate 
immune cells to identify pathogen associated molecular patterns (PAMPs), which are 
associated with microbial pathogens and viruses or endogenous danger signal released by 
damaged cells (Joffre et al, 2009, Fujii et al, 2004, Le Bon et al 2001). It is suggested that the 
lack of T cell stimulation in cancer is caused by altered DCs with decreased functions. The 
circulating blood DCs’ number decreases in melanoma and the number of total DCs decreases 
as melanoma progress. There is a minimal recruitment and a low activation of DCs found 
within renal cell carcinoma (Troy et al, 1998). In addition of the low activation, IL-12 
production needed by T cell is also impaired in cancer patients’ DCs (Della et al, 2003). The 
number and allo-stimulatory activity of myeloid DCs are lower in pancreatic cancer patients 
than in healthy individuals (Yanagimoto et al, 2005). DCs that infiltrate non-small cell lung 
cancer are blocked in immature state and although they could be induced into maturation by 
TLR4 stimulation, they display a poor APC function even after the TLR stimulation (Perrot et 
al, 2007). 
The second category includes the negative regulation of immune responses. There are 
several negative regulation mechanisms that are suggested in cancer patients: (1) expansion of 
immune suppressor cells, (2) expression of co-inhibitory molecules and (3) production of 
immunosuppressive cytokines or other suppressive factors. 




Several immune suppressor cells are found in cancer patients, including regulatory T 
cells (T-regs), Tumor associated macrophages (TAMs) and Myeloid-derived suppressor cells 
(MDSCs) (reviewed in Allavena et al, 2008; Gabrilovij and Nagaraj, 2009).  
T-regs are defined as a subset of T cells that functionally supress the immune 
responses. T-regs suppress the immune responses through (1) contact dependent mechanism 
involving B7-H4 expression on antigen presenting cells (APCs) which negatively regulate T 
cell responses, (2) CTLA-4-mediated induction of IDO expression, (3) IL-10 and 
Transforming Growth Factor-TGF-expressions or (4) direct killing of effector cells via 
granzyme and perforin (reviewed in Zou, 2006; Gross and Walden, 2008). There are several 
possible mechanisms that can explain the increased frequency of T-regs in the tumor 
microenvironment. Firstly, abundant expression of CCL22 in the tumor microenvironment 
stimulates T-reg infiltration in tumors. Secondly, tumor microenvironment contains molecules 
that can alter APC differentiation and function, which will then induce T-reg expansion. 
Lastly, tumor microenvironment can produce a high level of TGF- which will convert 
normal T cells into T-regs. Higher frequencies of T-regs are found in peripheral blood of 
varieties of cancer patients. Studies of T-regs in humans show a potent immunosuppressive 
activity in vitro. An accumulation of T-regs in patients also indicates a reduced survival in 
patients (reviewed in Zou, 2006; Curiel, 2007). 
Accumulating evidence suggests TAMs actively promotes tumor growth and 
development. Several animal model experiments suggest TAMs promotes tumor progression 
and angiogenesis by producing pro-angiogenic cytokines (e.g., TNF-IL). TAMs isolated 
from tumors are generally less efficient in presenting antigens. TAMs are unable to produce 
IL-12 needed in anti-tumor responses mediated by NK cells and T cells. TAMs are also 
shown to produce immunosuppressive cytokine IL-10 and TGF- and to express programmed 
death ligand (PD-L)-1 (reviewed in Quatromoni and Erulanov, 2012; Pollard, 2004). 
MDSCs are described as a mixture of cells in immature state of myeloid origin. 
MDSCs have suppressive capacity on adaptive immune response and these cells were 
reported to be found in blood of varieties of cancer patients. Several mechanisms of MDSCs 
to suppress immune responses have been described. MDSCs are reported to upregulate the 
production of reactive oxygen species (ROS). A combination of ROS and nitric oxide (NO) 
forms peroxynitrite that could damage proteins, including those regulating MHC-II 
expression and T cell apoptosis. MDSCs can inhibit NK cell cytotoxicity by inhibiting 
NKG2D expression and IFN- production. Aside from their suppressive effect on adaptive 




immune responses, MDSCs are also able to regulate innate immune responses by increasing 
IL-10 production, suppressing macrophage IL-12 production and activating and enhancing T-
regs (reviewed in Gabrilovij and Nagaraj, 2009; Sinha et al, 2007; Lindau et al, 2013). 
To date, two key co-inhibitor molecules have been identified to affect T cell functions: 
cytotoxic T lymphocyte associated antigen 4 (CTLA-4) and programmed cell death 1 (PD-1). 
CTLA-4 in resting cells is intracellularly localized to clathryn-associated complexes. By 
activation, CTLA-4 will be relocated to the cell surface, which is a temporary state, and will 
be rapidly reinternalized again. CTLA-4 binds CD80 and CD86, with 20-40 folds higher 
affinity than of CD28. CTLA-4 ligation antagonizes early T cell activation leading to a 
decrease of some stimulatory cytokines (e.g., IL-2), an increased immunosuppressive 
cytokines production, a cell cycle arrest, a modulation of TCR signaling and a decreased T 
cell proliferation. CTLA-4 has also been implicated in the modulation of T-regs by enhancing 
T-reg immunosuppressive activity (Jago et al, 2004; Fife and Bluestone, 2008; Mocellin and 
Nitti, 2013).   
PD-1 is a glycoprotein, which carries immunoreceptor tyrosine-based inhibitory motifs 
(ITIM) and immunoreceptor tyrosine-based switch motif (ITSM). The binding of PD-1 with 
PD-L1 and PD-L2 will cause phosphorylation on ITIM and ITSM. PD-1/PD-L1 interaction 
decreases cytokine synthesis and glucose metabolism, blocks T cell proliferation and survival. 
Signaling through PD-1 ligation leads to a decreased IFN- production, a decreased T cell 
proliferation, an increased T cell apoptosis and a blockage of CD28-mediated activation (Fife 
and Bluestone, 2008; Gianchecchi et al, 2013).  
CTLA-4 and PD-1 are also suggested to play a critical role in maintaining peripheral 
tolerance. In this state, T cells are not deleted but in a state of muted responsiveness to antigen 
challenge, a state called anergy (Fife and Bluestone, 2008). Observations in mice show that 
anergic T cells but not functional memory T cells express a high level of negative regulator 
PD-1 (Barber et al, 2006) and a blockade of the negative regulators signaling could reverse 
the T cell anergy to some extent (Golden-Mason et al, 2009).  
CTLA-4 and PD-1 are thought to play important roles affecting T cell functions in 
tumor. Lymphocytes from peripheral blood and tissue samples from oral squamous cell 
carcinoma patients express higher levels of PD-1 compared with healthy individuals and the 
expression of PD-L1 is intense in oral squamous cell carcinoma sites (Malaspina et al, 2011). 
Within the tumor microenvironment, PD-1 ligands are often expressed by tumor and tumor 




stroma cells and correlated with unfavourable prognosis for patients (Gross and Walden, 
2008).  
The last mechanism of negative regulation discussed here is carried out by 
immunosuppressive cytokines or other suppressive factors. Vascular endothelial growth factor 
(VEGF) is reported to be secreted by many tumors. It is reported to have an angiogenic 
function and be able to inhibit DC differentiation and maturation (reviewed in Gross and 
Walden, 2008). Deregulation of the enzyme cyclooxygenase-2 (COX-2) in cancer leads to a 
production of abundant prostaglandin E2 (PGE2). PGE2 is able to promote proliferation, 
survival, angiogenesis, migration, invasion, and induce production of IL-10 (Greenhough et 
al, 2009). Intracellular adhesion molecule-1 (ICAM-1) is reported to be shed from tumor cells 
and able to block the binding of effector cells to their target. Adenosine produced by tumor 
cells can inhibit IL-12 production and induce IL-10 production. Activation of the enzyme 
indoleamine 2, 3-dioxygenase (IDO) has been implicated in a variety of primary tumor and 
demonstrated in tumor cell lines. IDO is an enzyme that catalyzes the first step of tryptophane 
degradation leading to kynurenine. T cells seem to be sensitive to a shortage of tryptophane 
and kynurenine is toxic to lymphocytes. IDO-mediated tryptophan deficiency inhibits T cell 
proliferation, sensitizes T cells to apoptosis and upregulates T-reg activity (reviewed in Gross 
and Walden, 2008; Frey and Monu, 2008, Hwu et al, 2000; Lee et al, 2002; Hill et al, 2007). 
Two well-known suppressive cytokines are IL-10 and TGF-. Immunosuppressive 
cytokines are important players in the immune system since a proper balance of pro- and anti-
inflammatory reaction is necessary for regulating it (Grütz, 2005). Self-limiting mechanisms 
are important to prevent an excessive activation of T cells that could cause damage to the 
host. This immune system homeostasis is necessary to make sure that immune system 
responds adequately to infections or injuries and then is negatively regulated back to the 
baseline. These two cytokines are detected in patients’ blood, primary tumor and sentinel 
lymph nodes and therefore have been proposed as major immunosuppressive cytokines in 
cancer (Polak, 2007).  
IL-10 is considered to be the key immunoregulator during inflammation triggered by 
infection or trauma to ensure the inflammation reaction will not be excessive and in the end 
damages the host. Human IL-10 is a 35 kD homodimer. IL-10 is produced by immune cells, 
including monocytes, dendritic cells, macrophages, B cells, T cells, NK cells, mast cells and 
granulocytes, and it is also produced by non-immune cells, such as epithelial cells and 
keratinocytes (reviewed in Iyer and Cheng, 2012). Since IL-10 is a cytokine normally 




expressed to limit the immune response, it has been suggested to play a role in inducing 
tolerance (Grütz, 2005).  
IL-10 activity is mediated by a heterodimeric IL-10 receptor composes of IL-10R1 and 
IL-10R2. IL-10 mainly uses the Janus kinase (JAK) family members and Signal Transducer 
and Activator of Transcription (STAT) transcription factors in its signaling pathway. The 
binding of IL-10 to its receptor will activate JAKs, which in turn phosphorylate two tyrosines 
(Tyr 446 and Tyr 496). Afterwards, STAT3 will bind to the receptor via SH2 domain and be 
phosphorylated. Additionally, STAT1 and STAT5 are activated. These transcription factors 
will form homo- and hetero-dimers and migrate to the nucleus to activate target genes. The 
activation of IL-10 leads to large changes of the expression profile of immune modulatory 
genes, which in effect will inhibit pro-inflammatory cytokines secretions, decrease antigen 
presentation and phagocytosis, and enhance inhibitory, tolerance and scavenger functions of 
the cells. The suppressor of cytokine signaling 3 (SOCS-3) is one of the target genes whose 
expression is induced by IL-10. SOCS-3 induction seems to be responsible for terminating IL-
10 activation (reviewed in Sabat et al, 2010, Ding et al, 2003).  
IL-10 is capable to inhibit the activities of T cells, B cells, NK cells, mast cells, 
monocytes and macrophages (Couper et al, 2008; Moore et al, 2001) with monocytes and 
macrophages appeared to be the primary target of IL-10 effect. IL-10 is reported to inhibit CC 
chemokines (MCP-1, MCP-5, MIP-1, MIP-1, MIP-3, MIP-3, RANTES, and MDC) and 
CXC chemokines (IL-8, IP-10, MIP-2, and KC) synthesis. Thus, IL-10 inhibits the 
productions of nearly all inducible chemokines involved in inflammatory reaction. IL-10 also 
inhibits the production of pro-inflammatory cytokines (IL-1, IL-6, IL-18, GM-CSF, G-CSF, 
M-CSF, TNF, LIF, and PAF). IL-10 also increases the expression of their natural antagonist 
and induces production of anti-inflammatory mediators such as IL-10 itself, IL-10R 
antagonist and soluble TNF- receptor. Furthermore, IL-10 inhibits IL-12, NO production, 
and expression of MHC class II and co-stimulatory molecules (reviewed in Moore et al, 2001; 
Sabat et al, 2010).  
IL-10 also has direct effects on T cells. It is reported to inhibit both proliferation and 
cytokine synthesis of CD4 T cells, which includes the production of IL-12 and IFN- by TH1 
and IL-4 and IL-5 by TH2. Upon CD4 T cell activation in vitro, the presence of IL-10 induces 
these cells to develop a regulatory phenotype (reviewed in Sabat et al, 2010). In contrast, IL-
10 has no direct inhibitory effect on the proliferation of CD8 T cells stimulated with anti-CD3 
mAb (Groux et al, 1998).  




Several investigations showed that IL-10 is produced in tumors. IL-10 is strongly 
expressed in basal cell carcinoma and squamous cell carcinoma (Kim et al, 1995).  IL-10 
mRNA is found in tissues of primary tumors and metastases but not in adjacent normal skin 
of patients with malignant melanoma (Krüger-Krasagakes et al, 1994). Serum IL-10 levels of 
advanced melanoma patients are higher than normal volunteers (Nemunaitis et al, 2001). 
Addition of exogenous IL-10 in culture enhances melanoma proliferation and prolongs the 
melanoma survival while blocking IL-10 decreases the proliferation (Yue et al, 1997). An in 
vitro study by Garcia-Hernandez and colleagues shows that IL-10 induces tumor proliferation 
and angiogenesis in the B16-melanoma model (Garcia-Hernandez et al, 2002).  
Investigators report that IL-10 induces CTL anergy by downregulating the expression 
of MHC class I and transporter associated with antigen processing (TAP) in human melanoma 
cells (Kurte et al, 2004). Expressed by tumor cells, it is suggested to increase the expression 
of nonclassical HLA class Ib molecules (i.e. HLA-G), which is thought to inhibit the cytolytic 
activity of NK cells and CTLs (Urosevic and Dummer, 2003; Gros et al, 2008; Le Gal et al, 
1999). Several groups suggest that it promotes tumor growth by blocking the induction of 
naïve T cells into CTLs (Steinbrink et al., 1999) and maintains T cell anergy by inducing the 
IDO (Lee et al, 2005). IL-10 is reported to hinder antigen presenting properties of DCs, thus 
impairing T cell responses against tumor (reviewed in Mocellin et al, 2005).  
Although IL-10 is generally accepted as a major immunosuppressive cytokine, 
conflicting evidence suggesting IL-10-mediated immune stimulation has also been reported. 
Injection of IL-10 after a booster vaccine enhances anti-tumor immunity and vaccine 
efficiency in one in vivo study by maintaining CD8 effector function (Fujii et al, 2001). 
Another study demonstrates that transfection of IL-10 gene into melanoma cells results in the 
loss of tumorigenicity in proportion to IL-10 secreted (Gerard et al, 1996). IL-10 is also 
reported to inhibit melanoma metastasis in mice via NK cells-dependent mechanism (Zheng 
et al, 1996).  
The other major anti-inflammatory cytokine suggested to play a role in cancer is TGF-
. TGF- is a pleiotropic cytokine, involved in numerous physiological and pathological 
processes, ranging from cell growth and differentiation, embryogenesis, reproduction, bone 
formation, carcinogenesis and immune response, among others. Targets of TGF- include 
CD4 T cells, CD8 T cells, dendritic cells, NK cells and macrophages.  In mammals, three 
TGF- forms have been identified (TGF-1, TGF-2 and TGF-3), and TGF-1 is the 
predominant isoform in the immune system. TGF- is synthesized as an inactive form 




composed of a TGF- dimer in association with the latency-associated protein (LAP). This 
latent form is secreted as such or forms a complex with latent TGF- binding protein (LTBP). 
TGF- is activated by degradation of LAP or alteration of its conformation. The active TGF- 
binds to a tetrameric complex of TGF-R1 and TGF-R2 and initiates TGF signaling 
(reviewed in Li and Flavel, 2008, Massague´, 2008). 
When active, TGF- binds to the receptor, the TGF-R2 will phosphorylate TGF-R1 
which in turn will phosphorylate SMAD proteins. The receptor-regulated SMADs (SMAD-1, 
2, 3, 5, and 8) are directly phosphorylated by TGF-R1 and will form complexes with the co-
mediator SMAD-4. These SMAD complexes will translocate to the nucleus and in 
conjunction with other nuclear co-factors regulate transcription of target genes. The inhibitory 
SMADs (i.e. SMAD-6 and 7) negatively regulate TGF- signaling by competing with 
receptor-regulated SMAD for receptor or SMAD-4 interaction and by targeting the receptor 
for degradation (reviewed in Shi and Massague´, 2003). 
TGF- plays a complex role during carcinogenesis. TGF- can be produced by tumor 
cells and immune cells such as T lymphocytes and DCs (Enk, 2005; Polak et al, 2007). In 
early stages TGF- can inhibit tumor growth but in later stages it can promote tumor growth 
(Javelaud et al, 2008, Lebrun, 2012). Alteration of TGF- signaling can have a significant 
effect on tumor initiation and progression but it can also function as a tumor suppressor (Yang 
and Moses, 2008). Different points of disruption in TGF- signaling have been described in 
cancer. Reduced expression of TGF-R1 or TGF-R2 is reported in lung, gastric, prostrate 
and bladder cancer. Loss of SMAD-3 expression is noted in gastric cancer and T cell 
lymphoblastic leukemia. SMAD-4 mutation is reported in pancreatic carcinoma and 
pancreatic cancer (reviewed in Massague´, 2008). In a mouse model, knockout of TGF-R 
resulted in a more aggressive adenocarcinoma tumor (Ijichi et al, 2006) and promoting 
squamous cell carcinoma (Guasch et al, 2007). Some human cancer cells express a high level 
of TGF- which impacts the tumor microenvironment, angiogenesis and metastasis (Leivonen 
and Kahari, 2007). Increased expression and secretion of different TGF- isoforms in 
melanoma cell lines compared with normal melanocytes are reported by several studies 
(Javelaud et al, 2008). Blocking TGF- signaling reduces pancreatic adenocarcinoma primary 
tumor growth and decreases the incidence of metastasis in vivo (Gaspar et al, 2007). TGF- 
can have a pro- or anti-tumor activity by affecting cell differentiation. TGF- can favor 
epithelial differentiation into less proliferative states partly through downregulation of 




inhibitor of differentiation DNA binding 1 (ID1) but TGF- may also activate carcinoma 
progenitor cells to have a high motility and become invasive mesenchymal derivatives 
(reviewed in Massague´, 2008). 
Another suggested mechanism to inhibit effector function is the immune modulation 
by the enhance production of tumor-derived factors. It is reported that chemokine (C-C motif) 
ligand 2 (CCL2) produced by melanoma resulted in a tumor associated macrophages (TAMs) 
recruitment and a greater level of angiogenesis. Tumor IL-6 is reported to skew the monocyte 
differentiation into TAMs (reviewed in Ilkovitch and Lopez, 2008).  
 
 





 This study was designed to investigate the role of IL-10 and TGF- in melanoma, with 
focus on the following objectives. 
General objective: to clarify the conflicting evidence about the role of IL-10 and TGF- in 
melanoma.  
Specific objectives:  
 To investigate both cytokines in situ by measuring the levels of expression of the two 
immunosuppressive cytokines, in relation to the expression of their responsive genes, 
in a large number of melanoma samples and compare them to the healthy skin samples 
since previous studies were done with small numbers of samples and comparisons 
were not done with healthy skin samples (Dummer et al, 1998, Krüger-Krasagakes et 
al, 1994, Itakura et al, 2011).  
 To study the active role of IL-10 and TGF- in suppressing immune responses using 
an anergic T cell in vitro model. 
 To evaluate the role of IL-10 and TGF- in the differentiation and maturation of 
tumor-associated DCs. 
  




2. Materials and Methods 
2.1. Clinical materials 
Melanoma metastases from tumor surgeries and skin samples from healthy individuals 
from breast reduction surgeries and foreskins were obtained from the dermatosurgery, 
dermatohistopathology and the tumor bank of the Department of Dermatology, and from the 
Gynecological Department of the Charité. The samples were shock-frozen in liquid nitogen 
and cryopreserved. Several melanoma cells were developed into cell lines. The melanoma cell 
lines used in the in vitro experiments were ChaMel84 and SK-Mel-28. ChaMel84 was 
established in our lab from the tumor of one of the patients. SK-Mel-28 was obtained from 
American Type Culture Collection (ATCC). 
This study had been reviewed and approved by the ethic commission of Charité under 
the title ‘Mechanism of immune suppression in tumor’ on 18 September 2008 (EA1/157/08). 
 
2.2. Methods 
2.2.1. Preparation of human Peripheral Blood Mononuclear Cells  
Whole blood was obtained from a buffy coat. Peripheral Blood Mononuclear Cells 
(PBMCs) were obtained by standard density gradient centrifugation using Ficoll-Paque 
(density 1.077 g/ml) (Biochrom, Berlin, Germany). Blood was diluted with an equal volume 
of PBS (Gibco, Darmstadt, Germany). Diluted blood was layered on top of 15 ml Ficoll 
solution (Biochrom, Berlin, Germany) using a 50 ml tube to create a Ficoll gradient by 
centrifugation for 20 minutes at 1000xg at room temperature, with the brake off. PBMCs were 
collected from the Ficoll : plasma interface and washed twice by PBS. Cells were 
resuspended in RPMI medium (RPMI, 1 mM L-Glutamine-L-Alanine, 1% 
penicillin/streptomycin, and 10% FBS) (Biochrom, Berlin, Germany). 
 
2.2.2. CD4 and CD8 T cell isolation 
T cells were isolated from PBMCs using Dynabeads FlowComp (Invitrogen, 
Darmstadt, Germany). Isolation was done according to the manufacturer’s instruction with 
few modifications. The product is intended for positive magnetic isolation of CD4 or CD8 T 
cells from human PBMCs. 1x108 PBMCs were incubated with 25 µl Human biotinilyted-CD4 




or -CD8 antibodies, which will bind to the target cells, for 10 minutes at 4°C and then washed 
with isolation buffer (PBS supplemented with 0.1%BSA (Sigma Aldrich, Steinheim, 
Germany)). Cells that have bound the specific antibodies were incubated with 75 µl 
Flowcomp Dynabeads (superparamagnetic beads coated with streptavidin) for 15 minutes at 
the room temperature. Cells bound to Dynabeads through the streptavidin-biotin interaction 
were separated from other cells by placing the tube containing the mixture of cells on a 
magnet. Bound cells stayed on the tube and the unbound cells were washed off by an isolation 
buffer. Beads were later removed from the cells by incubating the cells with 1 ml FlowComp 
Release Buffer to break the biotin-streptavidin interaction. 
 
2.2.3. Dendritic Cell Generation 
Monocytes were sorted from PBMCs using Dynabeads FlowComp (Invitrogen, 
Darmstadt, Germany). Separation was done according to the manufacturer’s instruction. The 
product is intended for positive magnetic isolation of CD14 cells from human PBMCs. 5x107 
PBMCs were incubated with 25 µl Human biotinylated-CD14 antibodies for 15 minutes at 
4°C and then washed with isolation buffer (PBS supplemented with 0.1%BSA). Cells that 
have bound the CD14 antibodies were incubated with 75 µl Flowcomp Dynabeads 
(supermagnetic beads coated with streptavidin) for 20 minutes on ice. Cells bound to 
Dynabeads through the streptavidin-biotin interaction were separated from other cells by 
placing the tube containing the mixture of cells on a magnet. Bound cells stayed on the tube 
and the unbound cells were washed off by an isolation buffer. Beads were later removed from 
the cells by incubating the cells with 1 ml FlowComp Release Buffer to break the biotin-
streptavidin interaction. In some experiments, the adherence method to isolate monocytes was 
used. When the adherence method was used, 1x107 PBMCs were put into a small culture flask 
(Nunc, Schwerte, Germany) for 1-2 hours, at 37°C. The non-adherent cells were washed off 
and the adherent cells were washed with cold PBS 4 more times.  
Monocytes were cultured at 1x105cells/well in 12 well plates (TPP, Berlin, Germany) 
in RPMI medium supplemented with 50 ng/ml GM-CSF (Aesca, Traiskirchen, Austria) and 
50 ng/ml IL-4 (Promokine, Heidelberg, Germany). The cytokines were added on day 0 and 
day 4. Maturation of DCs was done by adding cytokine cocktail (10 ng/ml IL-1, 25 ng/ml IL-
6, 10ng/ml TNF- (Miltenyi, Bergisch Gladbach, Germany)) on day 5. Cells were harvested 
on day 7 with cold PBS.  




2.2.4. RNA isolation 
RNA isolation was done using RNA isolation kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instruction. Tissue (40-80 mg) was put into a 15 ml tubes 
with 700 µl lysis buffer to lyse the cells. Further disruption of tissue was done using ultra-
turrax homogenizer (IKA, Staufen, Germany) for 5 seconds on ice. Samples then treated with 
10 µl proteinase K solution for 10 minutes at 55°C to remove proteins. Debris was removed 
by centrifugation and supernatant was mixed with 0.5 volumes ethanol and centrifuged 
through RNeasy spin column, where RNA will bind to the silica membrane. Traces of DNA 
were removed by DNAse treatment. DNAse and any contaminant were washed away by a 
wash buffer and RNA was eluted in RNase-free water. When cells were used in RNA 
isolation, the number of cells used was 1x106 cells.  
RNA concentration was measured with a Qubit fluorometer (Invitrogen, Staufen, 
Germany) according to the manufacturer’s instruction. Sample was diluted 20 times with 
Quant-it working solution (Invitrogen, Staufen, Germany). The assay was performed at room 
temperature. Calibration was done using the calibration standard provided by the company. 
 
2.2.5. cDNA synthesis 
cDNA generation was done using Super Script III kit (Invitrogen, Staufen, Germany) 
to synthesize first-strand cDNA from total RNA according to the manufacturer’s instruction. 
The primer used in the synthesis was cDNA-3’ Primer (AAG CTG TGG TAA CAA CGC 
AGA GTC GAC TTT TTT TTT TTT TTT TTT TTT TTT TTT TTT VN). cDNA synthesis 
mixture (20µl) contained 5xRT buffer (4 µl), 10 mM DTT, 200 u SuperScript III Enzyme, 50 
pmol cDNA-3 primer, 1 µM dNTP mix and 1 µg RNA. The cycling condition comprised of 
denaturation at 50oC for 5 minutes, annealing and cDNA synthesis at 50oC for 60 minutes and 
termination at 72oC for 15 minutes.  
  




2.2.6. Measurement of cytokine production by ELISA 
Supernatants were collected at different time points of experiments. Cytokine 
production was measured by a sandwich ELISA. The procedure was run in duplication. The 
concentrations of antibodies used in ELISA were as listed: 
Cytokine detection Capture antibody Detection antibody 
IL-10 (eBioscience, Frankfurt, Germany) 2 µg/ml 1 µg/ml 
IL-12 (BioLegend, Fell, Germany) 2 µg/ml 2 µg/ml 
IFN- (Thermo Scientific, Schwerte, Germany) 2 µg/ml 2 µg/ml 
TGF-(eBioscience, Frankfurt, Germany) 6.25 µg/ml 2.5 µg/ml 
 
Capture antibody was diluted in PBS, except for the IL-12 antibody which was diluted 
in coating buffer (0.1 M NAHCO3, 0.03 M Na2CO3, pH 9.5 (Merck, Darmstadt, Germany)), 
and incubated overnight at 4oC to coat the plate. After washing the plate, blocking solution 
(1%BSA in PBS) was added into the well for one hour at the room temperature to coat any 
plastic surface on the well that remained uncoated by the captured antibody.  Sample 
supernatant (50 µl) was then added into the well and incubated for 90 minutes at room 
temperature to let the antigen binds to the immobilized (capture) antibody. To activate latent 
TGF-1 to immunoreactive TGF-1 in the cell culture supernatant, supernatant was incubated 
with 0.1 ml 1 N HCl (Merck, Darmstadt, Germany) for 10 minutes, followed by neutralization 
using 0.1 ml 1.2 N NaOH (Carl Roth, Karlsruhe, Germany). Plate was washed to remove the 
unbound proteins. Detection antibody conjugated with biotin was diluted in reagent diluent 
(1% BSA in PBS) and incubated for 90 minutes at room temperature to let the antibody binds 
to the antigen of the immobilized protein bound with the capture antibody. After removal of 
excess detection antibody, streptavidin conjugated to alkaline phosphatase (AP) (R&D 
Systems, Wiesbaden, Germany) was used with 1000 times dilution, incubated for 30 minutes 
at room temperature to let streptavidin bind to biotin-conjugated antibody. As substrate, 1 
mg/ml pNPP (Sigma Diagostic, Steinheim, Germany) diluted in detection buffer (1 M TRIS-
Cl, pH 9.5 (Merck, Darmstadt, Germany)) was used. Optical density was determined using an 









2.2.7. Flow cytometry analysis 
Phenotypic analysis of cell surface molecule expression was done by flow cytometry. 
Cells were stained with following fluorescent antibodies against: CD3, CD4, CD8, 
(Biolegend, Fell, Germany), CD11c, CD14, CD25, CD45RO, CD69, CD71, CD80, CD83, 
CD86, CTLA-4, PD-L1, HLA-DR (BD Bioscience, Heidelberg, Germany), and PD1 
(eBioscience, Frankfurt, Germany). Cells were collected and washed one time with FACS 
buffer (BD Bioscience, Heidelberg, Germany). After washing, cells were stained with 
antibodies against cells surface molecules (1:25-1:200 in 100 µl FACS buffer (BD 
Bioscience, Heidelberg, Germany) for 20 minutes at room temperature. Cells were washed 
again one time with FACS buffer and then analyzed by FACS Calibur (BD Bioscience, 
Heidelberg, Germany) using a Cell Quest Pro version 4.0.2 software (BD Bioscience, 
Heidelberg, Germany). 
For Granzyme B measurement, cells were permeabilized using fixation and 
permeabilization buffer (eBioscience, Frankfurt, Germany). After staining the cells with cell 
surface molecules’ antibody, cells were fixed and permeabilized. For detection, fluorescent 
antibody against granzyme B (Caltag, Darmstadt, Germany) (1:25 in 100 µl FACS buffer) 
was used. Staining was done for 30 minutes at room temperature. 
 
 
2.2.8. mRNA quantification by qPCR 
Quantification of the expression level of targets was done using a SYBR Green real 
time PCR detection method (SABiosciences, Hilden, Germany). Total mRNA from skin 
cancer patients and healthy donors were isolated from frozen cells or tissue and reverse 
transcribed into cDNA. Amplification of target genes by commercially available primers 
(SABiosciences, Hilden, Germany) using these cDNA as a template was done to quantify the 
expression level of the target genes. RT-PCR amplification mixtures (13 µl) contained 50 ng 
cDNA, 2x SYBR Green Master Mix buffer (6.5 µl), and 380 nM forward and reverse Primers. 
The reactions were run in duplication on Applied Biosystem 7500 Real-Time PCR System 
(Applied Biosystem, Darmstadt, Germany). The cycling condition comprised of 10 minutes 
polymerization activation at 95oC, 40 cycles of 95oC for 1 minute and 60oC for 1 minute, and 
dissociation at 95oC for 15 seconds, 60oC for 1 minutes and 95oC for 15 seconds. The 
following target genes were tested: IL-10, TGF-, TGF-R1, and IL-10R, and SMAD-7 and 
SOCS-3. To study whether the cells in the local microenvironment can respond to these 




cytokines, the expression of their receptors, TGF-R1 and IL-10R1, were measured. 
Activation of TGF- was determined by measuring the expression of SMAD-7, since SMAD-
7 expression increases when TGF- signaling is activated. The expression level of SOCS-3 
was also measured as a marker of IL-10 induction as IL-10 induces SOCS-3 expression. 
Quantitative results were normalized to geometric averaging of three internal control genes to 
get a more accurate normalization than just using one internal control. Nine housekeeping 
genes were tested to be used as internal control (B2M, HMBS, SDHA, GAPD, RPL13A, 
HPRT, YWHAZ, UBC, and ACTB).  The sequence of primers was listed in Table 1.  
 
Table 1. Primers sequence 
Primer Forward primer Reverse Primer 
ACTB CTGGAACGGTGAAGGTGACA AAGGGACCTTCCTGTAACAATGCA 
B2M TGCTGTCTCCATGTTTGATGTATCT TCTCTGCTCCCCACCTCTAAGT 
GAPD TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
HMBS GGCAATGCGGCTGCAA GGGTACCCACGCGAATCAC 
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 
RPL3A CCTGGAGGAGAAGAGGAAAGAGA TTGAGGACCTCTGTGTATTTGTCAA 
SDHA TGGGAACAAGAAGGGCATCTG CCACCACTGCATCAAATTCATG 
UBC ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT 
YWHAZ ACTTTCCTACATTGTGGCTTCAA CCGCCAGGACAAACCAGTAT 
 (Vandesompele et al, 2002) 
 
 
PCR was done to eliminate primers with unspecific results (UBC and ACTB). Three 
housekeeping genes (SDHA, GAPD, and HPRT) were chosen based on the stability of 
expression level in different melanoma samples. The stability was calculated using the 
geNorm software. Prior to measure the expression of target genes in samples, amplification 
efficiency for each primer was calculated using the equation: 
E = 10 ( -1/slope) 
A five point standard curve of each primer using a 2-fold serial dilution starting from 250 ng 
was used. PBMC (2x106 cells/ml) stimulated with 100 ng/ml LPS, 500 ng/ml Ionomycine and 
10 ng/ml PMA (Sigma Aldrich, Steinheim, Germany) was used as a template for positive 
control. The validity of standard curve was checked by confirming the slope that was falling 
between -3.3 to -3.8 (critical factors for successful real time PCR, qiagen, 2006). 
 




Amplification efficiency for each primer was shown in Table 2. 












The Ct values were transformed into quantities. Calculation on relative expression value was 
calculated using the equation: 
Q = E 
(minCt-sample Ct)
 
where  Q : quantity 
 E : amplification efficiency = 10 ( -1/slope) 
 minCt : lowest Ct value = Ct value of the sample with the highest expression 
 
Relative quantification of target gene was then normalized to housekeeping genes: 
Normalization of  GOI : QGOI/NF 
where NF : Geomittel of 3 HKG = (QGAPD + QHPRT + QSDHA)/3 
 
2.2.9. Proliferation assay 
Proliferation assay was done using flow cytometric analysis of cell division by CFSE 
dilution. CD4 T Cells were washed with PBS then incubated with 3-4 mM CFSE (Invitrogen, 
Darmstadt, Germany) in PBS for 10 minutes at 37oC. Staining was stopped by adding cold 
RPMI medium and incubating for 5 minutes on ice. Cells were washed 3 times with RPMI 
medium and used for proliferation assay. 2x105 CD4 cells/well were used in proliferation 




assay. Stimulation for proliferation was done by adding 1x104cells/well DC or 4x104cells/well 
tumor cells into the well. The flow cytometry analysis was done 5 days later. The MFI and 
percentage of low-CFSE-stained cells of each group were calculated. The percentages of low-
CFSE-stained cells represented the percentages of proliferating cells. The stimulation index 
represents the number of cells proliferating in response to stimulation divided by the number 
of cells undergoing background proliferation in un-stimulated condition. It is calculated by 
dividing the value of low-CFSE stained cells of stimulated T cells with the value of low-
CFSE-stained cells of un-stimulated T cells. Expansion index represents the fold expansion of 
overall culture. It was calculated by dividing the total MFI of un-stimulated T cells with MFI 
of stimulated T cells. 
 
2.2.10. Statistical analysis 
The Student’s one-tailed independent t-test with unequal variances was used to assess 
statistical differences between two groups. The p value below 0.05 and 0.10 are considered 
significant.  
  





3.1. IL-10 and TGF- in melanoma and healthy skin   
The expression of IL-10 and TGF- in 21 melanoma samples was compared with 12 
skin samples from healthy individual by quantitative PCR (qPCR). IL-10 was detectable in 
both melanoma and healthy skin samples, showing a variety level of expression in both 
populations. Two melanoma samples had a medium level of IL-10 expression but most 
samples had a low expression level. On the contrary, most skin samples from healthy 
individuals had a high expression level of IL-10 with only two samples had a low expression 
level. Student t-test showed that the average expression of IL-10 in melanoma was 4.7-fold 
significantly lower than the expression in healthy skin (p value: 0.0051) (Fig. 1a). TGF- was 
also detectable in melanoma and healthy skin with heterogeneous results. Two melanoma 
samples had a high expression level of TGF-, eight samples had a moderate level and 11 
samples showed a low expression. Two healthy skin samples had a high expression of TGF- 
and ten samples had a moderate level. The average expression of TGF- was 1.7-fold lower in 
melanoma than in healthy skin samples (p value: 0.0190) (Fig. 1b). 
The expression of IL-10 and TGF- receptors were measured to analyze whether cells 
were able to respond to IL-10 and TGF- stimulation. IL-10R expression in melanoma and 
healthy skin samples showed heterogeneous expression levels. Two melanoma samples had a 
high expression of IL-10R, one sample had a moderate level and 18 samples had a low level 
of expression. Four skin samples from healthy individual had a high expression of IL-10R, 
three had a moderate level and five samples had a low level of expression. The average 
expression of IL-10R was 2.3-fold lower than the expression in healthy skin (p value: 0.0687) 
(Fig. 1c). TGF-R expression in melanoma and healthy skin also demonstrated a high variety. 
Two melanoma samples had a high expression level of TGF-R but 19 samples showed a low 
expression. One healthy skin showed a high expression of TGF-R, three had a moderate 
level and eight samples had a low level of expression. The average expression of TGF-R in 
melanoma was 1.7-fold lower than the expression in healthy skin (p value: 0.0953) (Fig.1d). 
Suppressor of Cytokine Signaling-3 (SOCS-3) is reported to be one of IL-10 
responsive genes as IL-10 induces SOCS-3 synthesis (Donnely et al, 1999), while SMAD-7 
expression is reported to be induced by TGF- stimulation (Zhao et al, 2000). Therefore the 
expressions of SOCS-3 and SMAD-7 as reporter genes were measured to study the response 




of cells to IL-10 and TGF- production. SOCS-3 expression in melanoma and healthy skin 
samples was various. One melanoma sample had a moderate level of SOCS-3 expression and 
20 other samples had a low expression level. Five skin samples from healthy individual had a 
high expression level of SOCS-3, two samples had a moderate level and five samples had a 
low expression level. The average expression of SOCS-3 in melanoma was 5.9-fold 
significantly lower than the expression in healthy skin (p value: 0.0036) (Fig. 1e). SMAD-7 
expression in melanoma and healthy skin samples was also heterogeneous. Three melanoma 
samples had a moderate level of SMAD-7 expression and 18 samples had a low expression 
level. Seven samples from healthy individual had a high expression of SMAD-7, two had a 
moderate level and three samples had a low expression level. The average expression of 
SMAD-7 was 8.3-fold significantly lower in melanoma than in healthy skin samples (p value: 











Fig.1. qPCR of 21 melanoma and 12 healthy skin samples. (a) IL-10, (b) TGF-, (c) IL-10R, (d) TGF-R, 
(e) SOCS-3 and (f) SMAD-7 expression levels were quantified by qPCR in duplicate. Quantitative 
results were normalized to geometric average of three internal control genes (SDHA, GAPD and 
HPRT). Student’s t-test analysis (melanoma vs healthy skin samples); the p values are shown in the 
graphs. 
 




3.2. In vitro model for anergic T cells 
3.2.1. Establishing an in vitro anergic T cells model 
To test the active role of IL-10 and TGF- in suppressing immune response in 
melanoma, an in vitro model was designed to generate a model of anergic T cells found in 
tumors. Anergic T cells were defined as dysfunctional T cells which were unable to respond 
to stimuli. Factors that need to be determined in generating anergic T cells model were the 
ratio  between T cells and tumor cells in culture and the time needed by the T cells to rest to 
be able to respond to re-challenge. The melanoma cell line used in the in vitro experiments 
was ChaMel84 which had been established in our lab from one of the patients. ChaMel84 was 
chosen since a large number of tumor cells were needed in the experiments and ChaMel84 
grows rapidly in culture.  Anergic T cells were induced in vitro by incubating allogenic T 
cells with irradiated melanoma (30 Gy) in the presence of IL-2 (50 U/ml) in several steps.  
Titration experiments were done to determine the ratio of T cells to tumor cells needed 
to induce the optimal response and failed response of CD8 T cells. T cell proliferation was 
used to measure T cell responses. Different numbers of tumor cells were used to induce 5x105       
T cells. The ratios were: 1:1, 5:1, 10:1 and 20:1 (T cells: tumor cells). The numbers of T cells 
were counted every week for three weeks. T cell number decreased continually when T cells 
were co-cultured with the same number of tumor cells (1:1). T cell number decreased at the 
first 2 weeks of co-culturing for the other combinations (5:1, 10:1 and 20:1) and started 
increasing after 2 weeks. The 5:1 ratio showed the highest T cell number (5 folds compared 
with the beginning of co-culture) after 3 weeks, while 10:1 ratio tripled and 20:1 ratio doubled 
the original number (Fig. 2). For further experiments, the 5:1 group would be used as a 







Fig. 2. Titration experiments of T cells co-
cultured with tumor cells. Different 
numbers of tumor cells were added into 
wells to determine the optimal and failed 
induction. The ratios were 1:1, 5:1, 10:1 
and 20:1 (T cells: tumor cells). The numbers 
of T cells were counted every week for 
three weeks. The figure was a 
representative of 3 different independent 
experiments.  




Kinetics study was done to determine the time needed by T cells to rest to enable them 
to respond upon re-challenge. Firstly, tumor-specific T cells was selected and enriched by co-
culturing T cells with melanoma at 10:1 ratio for 10-11 days. Secondly, T cells were driven 
into anergic T cells by co-culturing T cells with the same ratio of melanoma (1:1 ratio). 
Functional T cells as a control group was generated by co-culturing T cells with melanoma at 
5:1 ratio. During the anergy induction, different co-culturing times were used (9, 12 or 18 
days). Lastly, T cells were re-challenged with melanoma at 5:1 ratio for 5 days to measure the 
ability of T cells to respond upon re-challenge. T cell proliferation, and Granzyme B and 
Interferon- (IFN-) productions were used to measure T cell responses. T cell proliferation 
was calculated as a stimulation index. The stimulation index represents the numbers of cells 
proliferating in response to stimulation divided by the numbers of cells undergoing 
background proliferation in un-stimulated condition.  
The results showed that the difference between donors was quite large. In 9 days co-
culture, donor 3 showed the biggest difference of T cell responses between control (5:1 
group) and anergic T cells (1:1 group), where the difference in proliferation rate was 30 fold, 
Granzyme B expression had a 1.5-fold difference and IFN- production had an 80-fold 
difference (Fig. 3a). Donor 2 had the least difference between control and anergic T cells, 
where proliferation had a 4-fold difference, Granzyme B expression a 1.4-fold difference and 
IFN- a 2-fold difference (Fig. 3a). In 12 days co-culture, donor 3 again showed the largest 
difference between control and anergic T cells, but with decreasing gap, with a 12-fold 
difference of proliferation, a 3-fold difference of Granzyme B and a 60-fold difference of 
IFN-production (Fig. 3b). Granzyme B production from 12 days culture (Fig. 3b) showed a 
different tendency with 9 and 18 days cultures (Fig. 3a and c), where donor 1 and donor 2 
showed no difference between control and anergic T cells. In contrast, stimulation index and 
IFN- production showed similar results on 9, 12 or 18 days co-culture (Fig. 3a-c). In 18 days 
co-culture, donor 3 showed the largest difference between control and anergic T cells, with a 
7-fold difference of proliferation, a 2-fold difference of Granzyme B and a 20-fold difference 
of IFN- production (Fig. 3c). Donor 1 had the least difference of proliferation (1.4-fold) and 
Granzyme B production (1.2-fold) while donor 2 had the least difference of IFN- production 
(1.9-fold) between control and anergic T cells (Fig. 3c). Nevertheless, all three donors showed 
the same tendency where all control T cells showed positive responses on all response 
parameters measured and anergic T cells failed to respond when T cells were co-cultured with 
tumor cells for 9 days.  Thus, 9 days co-culture was chosen in further experiments. 







Fig. 3 Kinetics experiments of T cells co-cultured with tumor cells. Anergic T cells were induced 
in vitro by stimulating T cells with irradiated melanoma (30 Gy) supplied with IL-2 (50 U/ml) in 
several steps. Firstly, tumor-specific T cells were selected and enriched by co-culturing T cells 
with melanoma at 10:1 ratio for 10-11 days. Secondly, T cells were driven into anergic T cells by 
co-culturing T cells with the same ratio of melanoma (1:1 ratio) in different culture times: (a) 9, 
(b) 12 and (c) 18 days. Functional T cells as a control group was generated by co-culturing T cells 
with melanoma at 5:1 ratio. Lastly, T cells were re-challenged with melanoma at 5:1 ratio for 5 
days to measure the ability of T cells to respond upon re-challenge. Data show results from 
three independent experiments. Stimulation index, Granzyme B and IFN- productions were 
used to measure T cell responses. 




To confirm that the anergic T cell in vitro model was not exclusive for the ChaMel84 
cell line, in vitro experiments using a different melanoma cell-line (SK-Mel-28) were done. 
SK-Mel-28 is a melanoma cell lines deposited at ATCC which has tumorigenic potential in 
nude mice. The selection process was done by co-culturing T cells with irradiated SK-Mel-28 
cells (10:1) for 10-11 days. To induce anergy, different numbers of SK-Mel-28 cells were 
used to stimulate T cells (T cells: SK-Mel-28 cells = 1:2, 1:1 and 5:1) for 9 days. The re-










The results showed that T cell proliferation was reduced in anergic T cells, where 
donor 1 had a 7-fold difference, donor 2 had a 1.3-fold difference and donor 3 had a 3-fold 
difference of proliferation between control and anergic T cells (Fig. 4a). Granzyme B 
production showed a different tendency where donor 2 and 3 showed less production on 
anergic T cells (2.7- and 1.9-fold difference, respectively) but donor 1 showed no decrease 
production of Granzyme B (Fig. 4b). IFN- production was also reduced after re-challenge in 
anergic T cells, with a 3.15-fold difference in donor 1, a 2.5-fold difference in donor 2 and a 
9-fold difference in donor 3 (Fig. 4c). One important thing to be noted was that the number of 
tumor cells needed to induce anergic T cells using this cell line was different. A double 
numbers of tumor cells compared with T cells were needed to induce anergy using SK-Mel-
28 cell lines. These experiments showed that the anergic T cells model could be generated in 
vitro using different melanoma cell lines. 
 
Fig. 4. T cell responses upon SK-Mel-28 stimulation. Firstly, tumor-specific T cells were selected 
and enriched by co-culturing T cells with melanoma at 10:1 ratio for 10-11 days. Second 
stimulation to induce anergy was done by co-culturing 1:2, 1:1 and 5:1 T cells vs tumor cells for 9 
days. Lastly, T cells were re-challenged with melanoma at 5:1 ratio for 5 days to measure the 
ability of T cells to respond upon re-challenge. (a) Stimulation index, (b) Granyzme B and (c) IFN- 
production were used to measure T cell responses. Only results from 1:2 and 5:1 groups are 
shown. Data show results from three independent experiments.  
 
 




3.2.2. IL-10 and TGF- in the in vitro anergic T cell model 
Based on kinetics experiments, in vitro experiments to study the active role of IL-10 
and TGF- in suppressing immune response against melanoma were done. In order to support 
the immunosuppression hypothesis, a positive correlation between IL-10 and TGF- 
production with immune suppression was expected, thus a higher expression of IL-10 and 
TGF- was expected to be found in the anergic T cell culture.  Firstly, tumor-specific T cells 
were selected and enriched by co-culturing T cells with melanoma at 10:1 ratio for 10-11 
days. Secondly, T cells were driven into anergic T cells by co-culturing T cells with the same 
ratio of melanoma (1:1 ratio) for 9 days. Functional T cells as a control group was generated 
by co-culturing T cells with melanoma at 5:1 ratio. Lastly, T cells were re-challenged with 
melanoma at 5:1 ratio for 5 days to measure the ability of T cells to respond upon re-
challenge. T cell responses were normalized to the control group since variations between 
donors were high. By normalization, the variations could be minimalized and the difference 
between groups would be clearer. The results are shown as fold changes compared with the 
control group.  
The results of the  in vitro experiment showed that anergic T cells (1:1  group) had 
significantly lower Granzyme B production (fold change: 0.72±0.23), lower proliferation 
(fold change: 0.53±0.28), and in particular lower IFN- production (fold change: 0.06±0.05) 
upon tumor cells re-challenge compared with the control T cells (5:1 group) (Fig. 5a). Three 
out of five donors showed a higher IL-10 production in the anergic T cell culture (1:1 group) 
compared with the control T cells (5:1 group) but two donors showed a lower IL-10 
productions in the anergic T cell group compared with the control group (Fig. 5b). IL-10 
production during anergy induction showed that there was no uniform tendency of increasing 
IL-10 production in the anergic T cell culture. Likewise, three out of five donors showed a 
higher TGF- production in anergic T cell culture compared with the control T cell culture 
but two donors showed a lower TGF- production in the anergic T cell group compared with 
the control group (Fig. 5c).  Thus, there was no co-linearity between IL-10 and TGF- 
productions with anergic T cell induction.  
 
   









3.2.3. T cell activation in the anergic T cell model 
 To analyze the T cell subsets in the culture, CD45RO expressions were measured at 
the end of anergy induction. Around 70% T cells were found to be memory T cells expressing 
CD45RO. Anergic T cell culture (1:1 group) had slightly more naïve T cells, expressing 
CD45RA, compared with the control group (%CD45RA+ cells: 26.72±13.46 vs 22.94±10.32) 
(Fig. 6a).  
To investigate the activation state of the anergic T cells induced in vitro, the 
expression of well-known activation and proliferation markers CD25, CD69 and CD71 and 
the IFN- production were analyzed. The results are shown as fold changes normalized to the 
control. Anergic T cells and control T cells had similar expression of CD71, however anergic 
Fig. 5. IL-10 and TGF-productions during anergic T cell induction. After tumor-specific T cell 
selection process, T cells were co-cultured with different numbers of tumor cells (5:1 as control and 
1:1 as anergic T cell model). (a) Five days after re-challenge, the percentage of low-CFSE-stained 
cells and percentage of Granzyme B positive cells were calculated by flow cytometry, while IFN- 
production was measured by ELISA.  Results from 5 different donors are shown as fold changes 
compared with the control group (5:1 group). Statistical analysis was done by student t-test (5:1 
group vs 1:1 group) p<0.05 is considered significant. (b) IL-10 and (c) TGF-produced during anergic 
T cell induction were measured by ELISA. 




T cells had a higher expression of the activation marker CD25 and CD69 compared with the 
control (fold change: 1.32±0.45 and 1.22±0.32, respectively) (Fig. 6b). Moreover, anergic T 
cells produced a significantly increased level of IFN- compared with the control (fold 




Kinetics experiments to further investigate the activation of T cells during anergy 
induction were done by co-culturing T cells with different numbers of tumor cells (T cells: 
tumor cells = 1:1, 2:1, 5:1 and 10:1) for 9 days. T cells were then re-challenged with tumor 
cells (5:1) for 5 days. IFN- production was used to measure the activation of T cells during 
anergy induction. T cell proliferation was used to determine T cell responses upon re-
challenge. Proliferation is shown as a stimulation index (SI).  
T cells co-cultured with tumor cells at 1:1 ratio produced 12,417 pg/ml IFN-during 
anergy induction. IFN- production was lower (mean value: 10,386 pg/ml) when T cells were 
co-cultured with tumor cells at 2:1 ratio compared with the 1:1 ratio and the lowest 




production reached when the 5:1 ratio was used (mean value: 7,925 pg/ml). IFN- production 
of T cells co-cultured with tumor cells at 10:1 ratio was higher (mean value: 14,479 pg/ml) 
than at 1:1 ratio. T cell responses upon re-challenge showed the exact opposite results where 
T cells co-cultured with tumor cells at 1:1 ratio had the lowest proliferation capacity (SI mean 
value: 2.1). The proliferation capacity was higher at 2:1 ratio culture (SI mean value: 11.8) 
and at 10:1 ratio (SI mean value: 4.8) compared with the 1:1 ratio. The highest proliferation 







Fig. 7. Kinetics experiments of anergic T cell induction. After tumor-specific T cell selection 
process, T cells were co-cultured with different ratios of tumor cells (1:1, 2:1, 5:1 and 10:1) for 9 
days. (a) IFN-production during anergy induction was measured by ELISA. (b) T cell proliferation 
was measured upon re-challenge by flow cytometry. Proliferation is shown as a stimulation index. 
Results are shown as mean values of 2 different donors.   




3.2.4. Co-inhibitor molecules on T cells co-cultured with tumor cells 
The expression of the co-inhibitor molecules PD-1 and CTLA-4 was investigated to 
study whether these molecules were involved in causing T cell anergy in this in vitro model. 
After tumor-specific T cell selection process, T cells were co-cultured with tumor cells at 
different ratios (1:1 and 5:1). Flow cytometry analyses of PD-1 and CTLA-4 expression were 
done at the end of anergy induction. Results are shown as fold changes compared with the 
control.  
PD-1 and CTLA-4 expressions on anergic T cells and control T cells showed no 
difference (Fig.8). No negative regulation by co-inhibitors molecules could be observed on 
anergic T cells generated in vitro.  
 
3.2.5.  Effect of IL-10 and TGF- on T cells co-cultured with tumor cells 
To answer whether IL-10 and TGF- could assist or interfere with anergic T cell 
induction, exogenous IL-10 or TGF- or antibodies against IL-10 or TGF- were added into 
T cells co-cultured with tumor cell at 5:1 ratio during anergic T cell generation. After tumor-
specific T cell selection process, T cells were further co-cultured with tumor cells (5:1) for 9 
days in the presence or absence of exogenous IL-10 (20 ng/ml) or TGF- (5 ng/ml) or 
antibody against IL-10 (5 µg/ml) or TGF- (10 µg/ml). A 5:1 ratio T cells to tumor cells 
culture without any addition of cytokine or antibody was used as a control group. A 1:1 ratio 
T cells to tumor cells without any addition of cytokine or antibody was used as a control of 
anergic T cell induction. T cells were then re-challenged with tumor cells (5:1) for 5 days. 
Fig. 8. Co-inhibitor molecule expression of T 
cells during anergy induction. T cells were co-
cultured with different numbers of tumor 
cells (5:1 as control and 1:1 as anergic T cell 
model). At the end of anergy induction, 
surface markers were analyzed by flow 
cytometry. Results are shown as fold 
changes compared with the control group 
(5:1 group) as mean values ± SD of 5 donors.  
 




IFN- production and T cell proliferation were used to measure T cell responses. Results of T 
cell responses were normalized and compared with the control group. Results are shown as 
fold changes compared with the control group. 
 As was shown in previous experiments, co-culturing T cells with tumor cells at 1:1 
ratio increased the IFN- production during anergy induction (fold change: 2.27±1.14) 
compared with the 5:1 ratio (control), and decreased the IFN- production and proliferation 
(fold change: 0.37±0.16 and 0.72±0.07,  respectively) upon re-challenge. Adding exogenous 
IL-10 to the 5:1 group did not make any change to the IFN- production during anergy 
induction or upon re-challenge but it decreased the proliferation upon re-challenge (fold 
change: 0.90±0.7). However, adding TGF- into the 5:1 culture significantly decreased the 
IFN- production during anergy induction (fold change: 0.69±0.22) and gave a better response 
upon re-challenge, with a 3-fold increase of IFN-production (fold change: 3.01±3.03) and a 
1.3-fold increase of proliferation (SI fold change: 1.31±0.18). Adding a combination of IL-10 
and TGF- to the 5:1 group did not change the IFN- production during anergy induction, but 
a higher IFN- production (fold change: 1.40±0.65) and proliferation (SI fold change: 
1.53±0.51) were observed upon re-challenge. Blocking IL-10 production in T cells co-
cultured with tumor cell at 5:1 ratio during anergy induction made no change to the IFN- 
production during anergy induction or to the T cell responses upon re-challenge. On the other 
hand, blocking TGF- in T cells co-cultured with tumor cells at 5:1 ratio during anergy 
induction led to a decreased IFN production during anergy induction (fold change: 
0.90±0.09), and an increased IFN- production (fold change: 1.77±0.82) upon re-challenged 
even though no increase of proliferation upon re-challenge was observed (SI fold change: 
0.98±0.09) (Fig. 9a and b).  
To study the effect of IL-10 and TGF- on anergic T cells, exogenous IL-10 or TGF- 
or antibodies against IL-10 or TGF- were added into T cells co-cultured with tumor cell at 
1:1 ratio during anergic T cell generation. After tumor-specific T cell selection process, T 
cells were further co-cultured with tumor cells (1:1) for 9 days in the presence or absence of 
exogenous IL-10 (20 ng/ml) or TGF- (5 ng/ml) or antibody against IL-10 (5 µg/ml) or TGF-
 (10 µg/ml). T cells were then re-challenged with tumor cells (5:1) for 5 days to determine T 
cell responses upon re-challenge using IFN- production and T cell proliferation as 
parameters. The results from measurement of T cell responses were normalized and compared 




with the 1:1 group (shown as fold changes) without any addition of cytokines or antibodies. 
As a positive control, the results of the measurement from the 5:1 group are shown.  
Co-culturing T cells with tumor cells at 5:1 ratio resulted in a lower IFN-production 
during anergy induction (fold change: 0.51±0.21), and a higher IFN- production and 
proliferation upon re-challenge (fold change: 2.98±1.13 and 1.40±0.14, respectively). 
Addition of IL-10 into the 1:1 group slightly increased the IFN- production during anergy 
induction and upon re-challenge (fold change: 1.15±0.15 and 1.27±82, respectively) but no 
changes on proliferation could be detected. Adding exogenous TGF- to the 1:1 group 
significantly reduced the IFN- production during anergy induction (fold changes: 0.54±0.12), 
opposed to a higher IFN- production upon re-challenge (fold change: 1.53±0.46) even 
though no change on proliferation was observed. Adding a combination of IL-10 and TGF- 
to the 1:1 group decreased the IFN- production during anergy induction (fold change: 
0.71±0.32) and increased the production upon re-challenge (fold change: 3.59±2.73) with no 
effect on proliferation. Blocking IL-10 production in T cells co-cultured with tumor cells at 
1:1 ratio decreased the IFN- production during anergy induction (fold change: 0.71±0.34), 
but no changes on T cell responses upon re-challenge was observed. Blocking TGF- in T 
cells co-cultured with tumor cells at 1:1 ratio significantly lowered the IFN-production 
during anergy induction (fold change: 0.87±0.08), but no significant changes on T cell 
responses upon re-challenge was detected (Fig. 9c and d).  
The above results showed large standard deviations. To confirm the results above, the 
experiments were repeated with fewer groups done in each experiment due to the limitation of 
resources and time in handling the experiments. In addition to IFN- production and T cell 
proliferation, Granzyme B production was also included to determine T cell responses. 
Results are shown as fold changes compared with the control group. 





Fig. 9. Effect of IL-10 and TGF- to T cells co-cultured with tumor cells. After tumor-specific T cell 
selection process, T cells were further co-cultured with different numbers of tumor cells (5:1 and 
1:1) for 9 days in the presence or absence of exogenous IL-10 (20 ng/ml) or TGF- (5 ng/ml) or 
antibody against IL-10 (5 µg/ml) or TGF- (10 µg/ml). T cells were then re-challenged with tumor 
cells (5:1) for 5 days. (a) IFN- production during anergy induction in the 5:1 ratio culture was 
measured by ELISA. (b) T cell responses upon re-challenge from the 5:1 group were determined by 
IFN- production measured by ELISA and cell proliferation measured by flow cytometry. (c) IFN- 
production during anergy induction in the 1:1 ratio culture was measured by ELISA. (d) T cell 
responses upon re-challenge from the 1:1 group were determined by IFN- production measured by 
ELISA and cell proliferation measured by flow cytometry. Results are shown as fold changes 
normalized to the control group as mean values ± SD of 3 donors. Student t-test analysis (control vs 
treatment), *p<0.1 and **p<0.05 are considered significant. 




In the first group of experiments, exogenous IL-10 (20 ng/ml) and TGF-ng/ml 
was added into T cells co-cultured with tumor cells at 5:1 ratio to study whether these 
cytokines could assist inducing T cells to become anergic T cells (Fig. 10). Addition of 
exogenous IL-10 during anergy induction increased slightly the IFN- production (fold 
change: 1.14±0.21), opposed to a decrease capacity to respond upon re-challenge, which was 
observed by a lower Granzyme B production (fold change: 0.80±0.33) and proliferation (SI 
fold change: 0.87±0.06), even though no change was detected on the IFN- production. 
Addition of exogenous TGF- during anergy induction decreased significantly the IFN- 
production to around 66% of the control’s level (fold change: 0.66±0.20). However, 
enhancement of the IFN- production to around 45% upon re-challenge was observed (fold 
change: 1.44±0.49) even though there was almost no difference in the Granzyme B 
production (fold change: 0.96±0.09) or proliferation (SI fold change: 1.01±0.15). Combining 
IL-10 and TGF- decreased the IFN- production during anergy induction (fold change: 
0.70±0.23). A double production of IFN- (fold change: 2.14±1.11) and a 13% increased of 
proliferation (fold change: 1.13±0.07) was observed upon re-challenge but there was no 
changes in Granzyme B production (fold change: 0.94±0.76) (Fig 10). 
 




 In the second group of experiment, exogenous IL-10 (20 ng/ml) and TGF- (5 ng/ml) 
were added to T cells co-cultured with tumor cells at 1:1 ratio to investigate whether addition 
of these immunosuppressive cytokines to the culture would help suppressing the T cell 
responses or on the contrary, interfering with the anergy induction. Results were normalized 
to T cells co-cultured with tumor cells at 1:1 ratio without any addition of cytokines and 
shown as fold changes compared with the control group. Addition of IL-10 only slightly 
decreased the IFN- production during anergy induction (fold change: 0.96±0.34), but could 
enhance T cell responses with a 4-fold increase of IFN- (fold change: 4.06±5.21), a 50% 
increase of Granzyme B production (fold change: 1.48±0.34) and a 5% increase of 
proliferation (SI fold change: 1.04±0.04) upon re-challenge. Addition of TGF- significantly 
decreased the IFN- production during anergy induction (fold change: 0.59±0.17) but doubled 
the IFN- production (fold change: 1.97±1.32) upon re-challenge although the proliferation 
significantly lowered (SI fold change: 0.67±0.29). No change was observed in the Granzyme 








In the third group of experiment, antibody against IL-10 (5 µg/ml) was added to T 
cells co-cultured with tumor cells at 1:1 ratio to further examine the role of endogenous IL-10 
in inducing T cell anergy. Results were normalized to T cells co-cultured with tumor cells at 
1:1 ratio without any addition of antibodies and shown as fold changes compared with the 
control group. IFN- production was lower when T cells were co-cultured with tumor cells at 
1:1 ratio in the presence of antibody against IL-10 (fold change: 0.83±0.05). There was an 
increase of Granzyme B production (fold change: 1.50±0.23) but no difference of IFN- 












3.3. Tumor-associated DCs in vitro 
3.3.1. Generation of tumor-associated DCs in vitro 
In addition to T cell in vitro experiments, melanoma cells were also co-cultured with 
monocytes to study the effect of melanoma cells on DC generation since melanoma has been 
suggested to induce defects on DCs via IL-10 and TGF- productions. To establish the 
optimal cell ratio for generating tumor-associated DCs in vitro, monocytes were differentiated 
into immature dendritic cells (iDCs) for 5 days and then 1x105 cells/well iDCs were further 
co-cultured with different ratios (1:1, 1:5 and 1:10) of irradiated melanoma cells (ChaMel84) 
in the presence of cytokine cocktail (IL-1, IL-6, TNF-). At the end of experiments, cells 
were collected and the MFI of CD14 was calculated by flow cytometry. Monocytes and 
macrophages express CD14 while DCs do not express CD14 therefore the loss expression of 
CD14 signifies the differentiation of DCs from monocytes. Measurements were gated on 
CD11c to exclude the tumor cells in analysis since in the culture set up only myeloid cells 
express CD11c. To study whether tumor cells alter DC capacity to induce T cell proliferation, 
DCs were co-cultured with allogenic CFSE-stained T cells (1:20) for 5 days. The percentages 
of low-CFSE-stained cells represented the percentages of proliferating cells. On day 5, low-
CFSE-stained T cells were calculated by flow cytometry. Data are shown as stimulation index 
fold changes compared with the control.  
CD14 expression on tumor-associated DCs was not altered (Fig. 13a). Tumor-
associated DCs cultured at 1:1 ratio had a slight increase capacity to induce CD4 T cell 
proliferation (SI mean value: 1.16) compared with the control. Tumor-associated DCs 
cultured at 1:5 ratio showed further increased DC capacity to stimulate CD4 T cells (SI mean 
value: 1.33). Tumor-associated DCs at 1:5 ratio and 1:10 ratio had similar capacity to induce 






















To confirm the robustness of DC generation in vitro setting, a different melanoma cell 
lines (SK-Mel-28) was used. To clarify the effect of melanoma cells on DC generation in 
differentiation and maturation stages, melanoma cells were added at the beginning of these 
two stages. Different ratios of melanoma cells were used in culture (monocytes : melanoma 
cells = 1:1 and 1:5) to study the effect of tumor burden on DC generation. To study the effect 
of melanoma cells on DC differentiation, 1x105 cells/well monocytes were cultured in the 
presence or absence of irradiated melanoma cells (SK-Mel-28) in a direct contact for 5-7 
days. Immature dendritic cells (iDCs) which were differentiated in the presence of tumor cells 
were called tumor-associated iDCs. To investigate the effect of melanoma cells on DC 
maturation, iDCs (1x105 cells/well) were generated from monocytes for 5 days and at day 5, 
induced into maturation by adding cytokine cocktail (IL-1, IL-6, TNF-) in the presence or 
absence of irradiated melanoma cells at ratios 1:1 and 1:5 (iDCs : melanoma). DCs induced 
into maturation in the presence of tumor cells were called tumor-associated mDCs. On day 7, 
cells were collected and the percentage of positive cells or MFI was calculated by flow 
cytometry. Measurements were gated on CD11c to exclude the tumor cells in analysis. DC 
capacity to induce T cell proliferation was investigated by co-culturing DCs with allogenic 
CFSE-stained CD4 T cells for 5 days.  
Fig. 13. Tumor-associated DCs generation. Monocytes were differentiated into iDCs for 5 days, and 
then further co-cultured with different numbers of tumor cells (1:1, 1:5 and 1:10). (a) CD14 
expression, gated on CD11c, was measured by flow cytometry. (b) On day 7, DCs were co-cultured 
with allogenic CFSE-stained CD4 T cells. The stimulation index represents the number of cells 
proliferating in response to stimulation divided by number of cells undergoing background 
proliferation in un-stimulated condition. Stimulation index are shown as fold changes normalized to 
control DCs. Results are shown as mean values of 2 donors.  
















Fig. 14. DC generation in the presence of melanoma cells (SK-Mel-28). (a-b) Different numbers 
of tumor cells were used in co-culture in a direct contact. In the 1:1 group, 1x105 monocytes 
were cultured with 1x105 irradiated tumor cells (SK-Mel-28) and in the 1:5 group, 1x105 
monocytes were cultured with 5x105 irradiated tumor cells. CD14 histogram of control iDCs and 
tumor-associated iDCs is shown as representative of 3 donors. %CD14+ is shown as mean values 
± SD of 3 donors.  (d) iDCs (1x105 cells/well) were generated for 5 days and on day 5, cytokine 
cocktail (IL-1, IL-6 and TNF-) together with irradiated tumor cells (1:1 and 1:5) were added. (c 
and e) On day 7, DCs were co-cultured with CD4 T cells (1:20). The stimulation index represents 
the number of cells proliferating in response to stimulation divided by number of cells 
undergoing background proliferation in un-stimulated condition. Stimulation index is shown as 
fold changes normalized to control DCs. Results are shown as mean values ± SD of 3 donors. 
Student’s t-test analysis (control vs tumor-associated iDCs or tumor-associated mDCs), **p<0.05 
and *p<0.1 are considered significant. 




In the control group, one peak showing a CD14 negative group could be observed 
from the histogram. However, in the tumor-associated iDCs, there was a shift of the CD14 
expression toward the positive value (Fig. 14a). Co-culturing monocytes with SK-Mel-28 
altered the CD14 expression as the percentage of CD14+ cells was higher on tumor-associated 
iDCs in corresponding to tumor burden (1:1 group: 23.22±18.63 and 1:5 group: 54.34±16.91) 
compared with the control iDCs (1.30±0.63) (Fig. 14b). However, CD14 expression level was 
not altered on the tumor-associated mDCs (Fig. 14d). The tumor-associated iDC capacity to 
induce CD4 T cell proliferation showed a significant 2-fold decrease in the 1:5 group (SI fold 
change: 0.56±0.25) compared with the control (Fig. 14c). The capacity to stimulate CD4 T 
cell proliferation of tumor-associated iDCs in the 1:1 group (Fig. 14c) or tumor-associated 
mDCs (Fig. 14e) was similar to the control DCs. These experiments showed that DC 
generation in the presence of different melanoma cell lines gave similar results. 
 
3.3.2. DC maturation induced by tumor cells 
To study whether tumor cells alone are sufficient to induce DC maturation, iDCs 
(1x105 cells/well) were generated for 5 days and then tumor cells (ChaMel84) were added 
(iDCs : tumor = 1:5) into the culture. As a control, cytokine cocktail (IL-1, IL-6, TNF-) was 
added to stimulate DC maturation. These experiments were set up in a cell culture well plate 
where a direct contact between iDCs and tumor cells occured or in a transwell system where 
iDCs had no direct contact with tumor cells. In a no contact group, a transwell membrane with 
0.4 µm pores was used. Using the transwell system, there would be no direct contact between 
tumor cells and iDCs but soluble factors and smaller molecules could still be exchanged in the 
culture. On day 7, MFI of CD80, and percentages of CD14+, CD83+ and HLA-DRhigh cells 
were calculated by flow cytometry. CD80, CD83 and HLA-DR are used to measure DC 
activation and maturation as these markers are upregulated on mature DCs. Measurements 
were gated on CD11c to exclude the tumor cells in analyses. MFI and percentages of 
activation and maturation markers were normalized to control DCs. 
The percentage of CD14+ in both direct contact and transwell assays increased when 
iDCs were induced with tumor directly in the absence of pro-inflammatory cytokines 
(33.09±28.59 and 26.60±26.50, respectively) compared with control DCs (2.80±2.24) (Fig. 
15a). The standard deviation was high because one donor had a very low percentage of 
CD14+ cell compared with the other two donors. The expression level of CD83 of DCs 
stimulated into maturation by tumor cells alone in direct contact and transwell assays were 




significantly lower compared with the control DCs (%CD83+: 0.26±0.14 and 0.19±0.07, 
respectively). The expression level of HLA-DR of DCs stimulated by tumor cells was lower 
in the direct contact assay and transwell assay (%HLA-DRhigh: 0.54±0.02 and 0.78±0.59, 
respectively) compared with the control but the difference was found to be statistically 
significant only in the direct contact assay. CD80 expression levels of DCs stimulated by 
tumor in both direct and transwell assays were significantly lower compared with the control 








Fig. 15. DC maturation induced by tumor cells. Monocytes (1x105 cells/well) were generated into iDCs 
and at day 5, tumor cells (1:5) were added with or without direct contact to stimulate DC maturation. 
As a control, cytokine cocktail (IL-1, IL-6, TNF-) were given to stimulate DC maturation. On day 7, 
percentages of (a) CD14+, (b) percentage of CD83+ and HLA-DRhigh cells, and MFI of CD80 were 
calculated by flow cytometry. Measurements were gated on CD11c to exclude tumor cells in the 
analysis. (c) On day 7, DCs were co-cultured with CD4 T cells. The stimulation index represents the 
number of cells proliferating in response to stimulation divided by number of cells undergoing 
background proliferation in un-stimulated condition. Results are shown as mean values ± SD of 3 
donors. Data are shown as fold changes normalized to control DCs. Student’s t-test analysis (control 
vs tumor associated DCs), **p<0.05 is considered significant. 
 




The capacity of DCs to induce T cell proliferation was also measured. Results are 
shown as stimulation index fold changes compared with the control. iDCs cultured with tumor 
cells had lower capacity to induce T cells in both direct contact and transwell assays but the 
differences between altered iDCs and control DCs were not statistically significant (SI fold 
change: 0.87±0.19 and 0.91±0.11) (Fig. 15c). 
 
3.3.3. Maturation of tumor-associated iDCs  
Previous experiments showed that tumor cells altered DC differentiation, leading to 
the next question whether the altered iDCs can still mature when given the necessary 
stimulation. To answer this question, 1x105 cells/well monocytes were differentiated into 
iDCs in the presence or absence of 5x105 cells/well tumor cells (1:5) for 5 days. On day 5, 
iDCs were stimulated with cytokine cocktail (IL-1, IL-6, TNF-) to induce DC maturation. 
The percentage of CD14+ cells increased 65-fold (27.79±1.25) on resulting matured 
tumor-associated DCs generated in the transwell assay and increased 163-fold (66.94±848) in 
the direct contact assay compared with the control iDCs (0.41±0.37) (Fig. 16a). The HLA-DR 
expression level was similar on control iDCs and tumor-associated DCs in the transwell assay 
but the HLA-DR expression decreased significantly when tumor-associated-DCs were co-
cultured in direct contact assay (MFI fold change: 0.68±0.22). Expression level of CD83 
decreased significantly on tumor-associated DCs in both direct contact and transwell assays 
(fold change: 0.29±0.17 and 0.33±0.11, respectively) compared with the control DCs (Fig. 
16b). 










The capacity of DCs to induce T cell proliferation was measured by co-culturing DCs 
with allogenic CD4 T cells for 5 days. Tumor cells were not removed from DCs co-culture in 
the direct contact assay but they were removed when transwell system were used. Results are 
shown as stimulation index fold changes compared with the control DCs. Tumor-associated 
DCs in the direct contact assay still had a low capacity to induce T cell proliferation even 
though they have been induced into maturation (SI fold change: 0.42±0.09). In the transwell 
system assay, the difference of capacity to stimulate T cell proliferation between tumor-
associated DCs and control DCs was statistically not significant (SI fold change: 0.74±0.44) 
(Fig. 16c). 
Fig. 16. Maturation of tumor-associated iDCs. iDCs (1x105 cells/well) were generated in the 
presence or absence of tumor cells (1:5). On day 5, cytokine cocktail (IL-1, IL-6, TNF-) were added 
to induce DC maturation. On day 7, (a) percentage of CD14+ and (b) MFI of HLA-DR and percentage 
of CD83+ cells were calculated by flow cytometry. Measurements were gated on CD11c to exclude 
the tumor cells in analysis. (c) On day 7, DCs were co-cultured with CD4 T cells. The stimulation 
index represents the number of cells proliferating in response to stimulation divided by number of 
cells undergoing background proliferation in un-stimulated condition. Data are shown as mean 
values ± SD of 3 donors. Data of activation markers and T cell proliferation are shown as fold 
changes normalized to control DCs. Student’s t-test analysis (control vs tumor-associated iDCs), 
**p<0.05 is considered significant. 
 




3.3.4. Modulation of DCs by tumor cells  
To investigate the effect of melanoma cells on DC differentiation, in relation to the 
expression levels of IL-10 and TGF- during co-culture, monocytes were cultured for 5-7 
days in the presence or absence of irradiated melanoma cells (ChaMel84) with or without 
direct contact. Different numbers of melanoma cells were used in culture to investigate the 
effect of tumor burden on DC differentiation. In 1:1 group, 1x105 monocytes were co-cultured 
with 1x105 melanoma cells and 1:5 group, 1x105 monocytes were co-cultured with 5x105 
melanoma cells. At the end of experiments, cells were collected and the percentage of CD14+ 
cells was calculated by flow cytometry. Measurements were gated on CD11c to exclude the 
tumor cells from the analyses. The morphology of cells was analyzed under microscope. 
Supernatants were also collected and IL-10 and TGF- production (pg/ml) were measured by 
ELISA.  
In the control group, one peak showing a CD14 negative group was observed from the 
histogram. However, in the tumor-associated iDCs, there was a shift of the CD14 expression 
toward the positive value (Fig. 17a). The morphology of the tumor-associate iDCs also 
changed. A mixture of cell population was observed, consisted of the typical round iDCs cells 
and macrophage-like cells which attached to the plate (Fig. 17b). In the 1:1 direct contact 
assay, the percentage of CD14+ cells on the tumor-associated iDCs increased 32 times and in 
the 1:5 group increased 97 times compared with the control (%CD14+: 14.85±3.97 and 
44.67±26.76 vs 0.46±0.25). In the transwell assay, the percentages of CD14+ cells were also 
significantly higher compared with the control iDCs but the difference between the 1:1 group 
and 1:5 group was not large (%CD14+: 9.96±4.74 and 15.93±10.08, respectively) (Fig. 17c). 
The experiments also showed that no cell contact was needed to affect the differentiation 
although the DC alteration was more pronounced in the direct contact assay. 
Control iDCs did not produce IL-10 in contrast to the tumor-associated iDCs. IL-10 
production in the direct contact assay increased in proportion to the number of tumor cells 
added into the culture (1:1 group: 190±117 pg/ml and 1:5 group: 285±161 pg/ml). IL-10 
production in the transwell assay also increased although not as much as in the direct contact 
assay (1:1 group: 126±67 pg/ml and 1:5 group: 201±94 pg/ml) (Fig. 17e).  
While control iDCs did not produce IL-10, they produced TGF- (568±25 pg/ml). In 
the tumor-associated iDCs 1:1 group direct contact assay, TGF- production was similar to 
the control (564±123.05 pg/ml) but in the 1:5 group, TGF- production was doubled 




(953±216 pg/ml). In contrast, TGF- production decreased around 50% in tumor-associated 
iDCs in both 1:1 and 1:5 groups in the transwell assay (255±300 and 332±414 pg/ml, 
respectively) (Fig. 17f). 
The capacity of iDCs to induce T cell proliferation was measured by co-culturing 
iDCs with CFSE-stained T cells (1:20) for 5 days. Tumor cells were not removed from iDCs 
co-culture in the direct contact assay but they were removed when transwell system were 
used. Results are shown as stimulation index fold changes compared with the control iDCs. 
Tumor-associated iDCs in the direct contact assay had significantly lower capacity to induce 
T cell proliferation, both in the 1:1 group (SI fold change: 0.69±0.18) and the 1:5 group (SI 
fold change: 0.58±0.25). Tumor-associated iDCs in the transwell assay also only had half the 
capacity of control iDCs to stimulate CD4 T cell proliferation (SI fold change 1:1 group: 
0.51±0.10 and 1:5 group: 0.52±0.47) (Fig. 17d). 
To investigate the effect melanoma cells on DC maturation, in relation to the 
expression levels of IL-10 and TGF- during co-culture, monocytes were generated into iDCs 
for 5 days, and then induced into maturation by adding cytokine cocktail (IL-1, IL-6, TNF-) 
in the presence or absence of melanoma cells (ChaMel84) for 2 days. Different numbers of 
melanoma cells were also used during DC maturation to study the effect of tumor burden on 
DC maturation. In the 1:1 group, 1x105 iDCs were co-cultured with 1x105 melanoma cells 
and in the 1:5 group, 1x105 iDCs were co-cultured with 5x105 melanoma cells. At the end of 
experiments, cells were collected and the expression of CD14, CD83 and HLA-DR were 
measured by flow cytometry. Measurements were gated on CD11c to exclude the tumor cells 
from the analyses. Data of activation and maturation markers are shown as MFI fold changes 
normalized to MFI of the control DCs generated in the absence of tumor cells. The 
morphology of the cells was analyzed per microscopy. Supernatants were collected and the 
productions of IL-12, IL-10, and TGF- were measured by ELISA. IL-12 production was 














CD14 expression level on tumor-associated mDCs was not altered when tumor cells 
were added during DC maturation (Fig. 18a). The morphology of tumor-associated mDCs 
also did not change (Fig. 18b). 
Tumor-associated mDCs in the direct contact assay showed a significant increase of 
CD83 expression level in proportion to the number of tumor cells added into culture. In the 
1:1 group the expression level increased 1.4 times (MFI fold change: 1.39±0.04) and in the 
1:5 group the expression level increased 1.9 times (MFI fold change: 1.94±0.56) compared 
with the control DCs. On the other hand, tumor-associated mDCs in the transwell assay 
showed a 1.3-fold increase of CD83 expression level only in the 1:5 group (MFI fold change: 
1.28±0.13), while the 1:1 group showed no difference in comparison with control DCs. HLA-
DR expression level showed a similar tendency in the direct contact assay. In the 1:1 direct 
contact assay, the HLA-DR expression level increased 1.2 times (MFI fold change: 
1.19±0.08) and in the 1:5 group the expression level increased 1.3 times (MFI fold change: 
1.33±0.26). In the 1:1 transwell assay, no difference of HLA-DR expression level could be 
observed. A slight increase of 1.1 times of HLA-DR expression level could be observed only 
in the 1:5 group (MFI fold change: 1.14±0.12) (Fig. 15c). In the 1:1 direct contact assay, a 
double amount of IL-12 was produced compared with the control (132.67±33.50 vs 59±52.16 
pg/ml) while the 1:5 group could produce 3 times more IL-12 (180±25.51 pg/ml). In the 
transwell assay, tumor-associated mDCs only showed a slight increase of the IL-12 
production (1:1 group: 63.33±55 pg/ml and 1:5 group: 66.33±58.04 pg/ml) (Fig. 18d).   
IL-10 production changed when tumor cells were added during DC maturation. In the 
1:1 direct contact assay, tumor-associated mDCs produced two times more IL-10 compared 
with control DCs (57±31 vs 24±42 pg/ml). The IL-10 production from tumor-associated 
mDCs in the 1:5 direct contact assay increased 7 times (181±123 pg/ml) compared with 
control DCs. In the transwell assay, similar results could be observed as the 1:5 group 
produced more IL-10 (160±50 pg/ml) compared with the 1:1 group (71±51 pg/ml) (Fig. 18f).  
TGF- production increased slightly when DCs were co-cultured with high numbers 
of tumor cells in the direct contact assay in comparison with control DCs (496±153 vs 
427±129 pg/ml). DCs co-cultured with a low number of tumor cells in the direct contact assay 
showed a similar TGF- production (314±114 pg/ml) with control DCs.  Similar observation 
were made in the tumor-associated iDCs differentiation and maturation, where TGF- 
production decreased when transwell assay were used (1:1 group: 291±318 pg/ml and 1:5 
group: 266±80 pg/ml) (Fig. 18g). 





















The capacity of DCs to induce CD4 T cell proliferation was measured by co-culturing 
DCs with CFSE-stained T cells (1:20) for 5 days. Tumor cells were not removed from DCs 
co-culture in the direct contact assay but they were removed when transwell system were 
used. Results are shown as stimulation index fold changes compared with the control DCs. 
The capacity to induce CD4 T cell proliferation of tumor-associated mDCs in the direct 
contact assay from the 1:1 group (SI fold change: 1.03±0.04) and the 1:5 group (SI fold 
change: 0.91±0.32) was similar with the control group. On the other hand, the capacity to 
stimulate CD4 T cells of tumor-associated mDCs from the transwell assay from both the 1:1 
group (SI fold change: 1.21±0.13) and the 1:5 group (SI fold change: 1.28±0.26) increased 
slightly (Fig. 18e). 
Previous experiments showed that DCs were altered when they were generated in the 
presence of tumor cells, including in the experiments using the transwell system. To 
investigate whether exosomes, which can flow through the transwell membrane affect the DC 
differentiation and maturation, tumor supernatant which was free from exosomes was used to 
generate DCs. Monocytes (1x105 cells/well) were cultured in medium only or medium 
containing 10% of exosome-free supernatant and 50% of exosome-free supernatant for 7 days 
to study the effect of exosome on DC differentiation. Different percentages of exosome-free 
supernatant were used to study the dose effect on DC generation. To study the effect of 
exosome on DC maturation, iDCs were generated for 5 days and then induced into maturation 
by cytokine cocktail (IL-1, IL-6, TNF-) on day 5 in the medium only or medium containing 
10% or 50% of exosome-free supernatant. At the end of experiments, cells were collected and 
the expression of CD14, CD83 and HLA-DR were measured by flow cytometry. Data of 
activation and maturation markers are shown as % positive cells fold changes normalized 
to % positive cells of control DCs generated in the absence of tumor cells. 
The results showed that iDCs generated in the exosomes-free supernatant had a higher 
percentage of CD14+ cells compared with the control iDCs in a dose dependent manner (10%: 
4.18±0.95 and 50%: 11.94±5.93 vs control: 3.77±2.79) (Fig. 19a). CD14 expression level was 
not altered in the DCs induced into maturation in the exosomes-free supernatant (Fig. 19b). 
No difference on CD83 and HLA-DR expression levels were observed when DCs were 
induced into maturation in 10% of exosome-free supernatant, but a slight increase of CD83 
expression (fold change: 1.32±0.56) and a significant increase of 60% of HLA-DR expression 
(fold change: 1.60±0.35) were observed when DCs were induced into maturation in 50% of 
exosome-free supernatant (Fig. 19c). From these results, it could be concluded that exosomes 




could be exempted in this study since exosomes-free medium used to differentiate monocytes 
were still able to alter the DCs. 
 





Previous experiments showed that IL-10 and TGF- were produced during the DC 
generation in the presence of tumor cells. To investigate which cells actually produced the 
cytokines during tumor-associated iDC generation, 1x105 cells/well monocytes were co-
cultured with 5x105 tumor cells/well (1:5) using a transwell system for 5 days. On day 5, 
iDCs and tumor cells were separated, and washed. Each cell type was further cultured in 
separate wells for 24 hours. At the end of experiments, supernatant were collected and then 
IL-10 and TGF- productions were measured by ELISA. To investigate which cells produced 
the cytokines during the generation of tumor-associated mDCs, iDCs were generated and at 
 Fig. 19. DC generation in exosome-free supernatant. (a) Monocytes (1x105 cells/well) were cultured 
in medium only or medium containing 10% of exosome-free supernatant and 50% of exosome-free 
supernatant for 7 days to study the effect of exosome on DC differentiation (b) iDCs were generated 
for 5 days and then on day 5 induced into maturation by cytokine cocktail (IL-1, IL-6, TNF-) in the 
medium only or medium containing 10% and 50% of exosome-free supernatant. Data are shown as 
mean values ± SD of 3 donors. Data of activation and maturation markers are shown as  fold changes 
normalized to control DCs. Student’s t-test analysis (control vs iDCs or Dcs cultured in exosome-free 
supernatant), *p<0.1, **p<0.05 are considered significant. 
 




day 5, 1x105 cells/well iDCs were induced into maturation by cytokine cocktail (IL-1, IL-6, 
TNF) addition for 24 hours in the presence of tumor cells (1:5) using a transwell system. 
After 24 hours co-culture, mDCs and tumor cells were separated and washed. Each cell type 
was further cultured in separate wells for 24 hours. At the end of experiments, supernatant 
were collected and then IL-10 and TGF- productions were measured by ELISA. IL-10 and 
TGF- productions in the supernatant of tumor cell-line alone were also measured as a 
control. 
During the generation of tumor-associated iDCs, tumor cells produced IL-10 
(161±115 pg/ml) while tumor-associated iDCs did not produce IL-10. As a control, IL-10 in 
tumor cell line supernatant alone was also measured (17 pg/ml). TGF- was produced by both 
tumor cells (531±75 pg/ml) and tumor-associated iDCs (334±113 pg/ml). TGF- could also 
found in the tumor cell line supernatant (285 pg/ml) (Fig. 20a). During the generation of 
tumor-associated mDCs, both tumor cells and tumor-associated mDCs produced IL-10 
(101±84 and 42±49 pg/ml, respectively). Tumor cells also produced 4 times more TGF- 
(460±56 pg/ml) than DCs (118±203 pg/ml) (Fig. 20b). 
 
 




To confirm that interaction of the two cell types was needed to induce IL-10 
production during the generation of tumor-associated iDCs, iDCs were generated in tumor 
supernatant. To study the IL-10 production during tumor-associated iDC differentiation, 
1x105 cells/well monocytes were cultured in medium only or medium containing 10% or 50% 
tumor supernatant. To study the IL-10 production during tumor-associated mDC generation, 
monocytes were generated into iDCs for 5 days, and then 1x105 iDCs were further cultured 
for 2 days in medium only or medium containing 10% or 50% tumor supernatant in the 
presence of cytokine cocktail (IL-1, IL-6, TNF-). At the end of experiments, IL-10 was 
measured by ELISA.  
 Control iDCs generated in medium alone produced 78±79 pg/ml IL-10. There was no 
difference of IL-10 produced by tumor-associated iDCs generated in 10% or 50% tumor 
supernatant compared with the control (52±45 and 80±116 pg/ml, respectively). A large 
standard deviation could be detected in this experiment because one sample produced a high 
amount of IL-10 while the other samples produced very little to none IL-10 (Fig. 21a). 
Similarly, no difference of IL-10 production could be detected between the control DCs 
(451±373 pg/ml) and tumor-associated DCs cultured in 10% or 50% tumor supernatant 







Fig. 21. IL-10 production during DC generation in tumor supernatant. (a) 1x105 monocytes were 
cultured in medium only or medium containing 10 % or 50% tumor supernatant. (b). iDCs were 
generated for 5 days and then on day 5, 1x105 iDCs induced into maturation by cytokine cocktail (IL-
1, IL-6, TNF-) in medium only or medium containing 10% and 50% tumor supernant. At the end of 
experiments, supernatant were collected and IL-10 production was measured by ELISA. Data are 
shown as mean values ± SD of 3 donors. 
 




To evaluate the effect of endogenous immunosuppressive cytokine produced during 
tumor-associated iDC or mDC generation, neutralizing antibodies against IL-10 and TGF-
were added into the culture.  1x105 cells/well monocytes were co-cultured with 5x105 tumor 
cells/well (1:5) in the presence or absence of antibody against IL-10 (5 µg/ml) or TGF-
µg/ml) for 5 days in a transwell system. On day 5, cytokine cocktail (IL-1, IL-6, TNF-
) was added to induce the maturation of iDCs. Matured DCs were then analyzed by flow 
cytometry for phenotypic changes and further co-cultured with allogenic CD4 T cells to 
investigate the DC capacity to stimulate T cell proliferation. Data of activation and maturation 
markers, as well as stimulation index, are shown as fold changes normalized to the control 
DCs generated in the absence of tumor cells. 
The percentage of CD14+ cells in tumor-associated iDCs culture was higher compared 
with the control iDCs (38.22±12.04 vs 0.70±0.52). Adding antibodies against IL-10 or TGF- 
into the culture did not change the percentage of the CD14+ cells (33.43±9.77 and 
39.54±14.01, respectively) in the tumor-associated iDCs culture (Fig. 22a). The HLA-DR 
expression level of matured tumor-associated iDCs was similar (fold change: 1.09±0.28) with 
the control DCs. The presence of antibodies against IL-10 and TGF- did not change the 
expression level of HLA-DR (fold change: 1.04±0.17 and 0.99±0.27, respectively) on the 
matured tumor-associated iDCs. The CD83 expression level on matured tumor-associated 
iDCs was significantly lower (fold change: 0.48±0.49) compared with the control DCs. 
Addition of antibodies against TGF- did not make any change to the CD83 expression level 
(fold change: 0.45±0.19) on matured tumor-associated iDCs but addition of antibody against 
IL-10 significantly increased the CD83 expression level (fold change: 0.60±0.41) on matured 
tumor-associated iDCs compared with the matured tumor-associated iDCs without antibody 
(fold change: 0.48±0.29) (Fig. 22b).   
The capacity of matured tumor-associated iDCs to induce CD4 T cell proliferation was 
similar (SI fold change: 1.19±0.27) with control DCs. Addition of antibody against TGF- 
into the culture did not change the capacity of matured tumor-associated iDCs to stimulate 
CD4 T cell proliferation (SI fold change: 1.06±0.11). Addition of antibody against IL-10 into 
the culture significantly increased the capacity of matured tumor-associated iDCs to induce 
CD4 T cell proliferation (SI fold change: 1.26±0.28) compared with the control DCs but 
compared with the matured tumor-associated iDCs cultured without antibody no significant 
changes were observed (Fig. 22c). 











The effect of immunesuppressive cytokines on the tumor-associated mDCs was 
investigated by generating iDCs for 5 days, then adding the cytokine cocktail (IL-1, IL-6, 
TNF-) along with tumor cells (1:5) into culture in the presence or absence of antibody 
against IL-10 (5 µg/ml) or TGF-µg/mlin a transwell system. DCs then phenotypically 
characterized by flow cytometry and then further co-cultured with allogenic CD4 T cells to 
investigate the DC capacity to stimulate CD4 T cell proliferation. Results of activation and 
maturation markers, as well as stimulation index, are normalized and shown as fold changes 
compared with the control DCs. 
Fig. 22. Effect of endogenous immunesuppressive cytokines production on tumor-associated iDC.  iDCs 
(1x105 cells/well) were generated in the presence of tumor cells (1:5), in the presence or absence of 
IL-10 (5 µg/ml) or TGF- (10 µg/ml) in a transwell system. On day 5, cytokine cocktail was added (IL-
1, IL-6, TNF-). DCs were further co-cultured with allogenic CD4 T cells for 5 days. (a) Percentage of 
CD14+ cells (b) CD83+ and MFI of HLA-DR were calculated by flow cytometry. Measurements were 
gated on CD11c. Data are shown as mean values ± SD of 4 donors. Results are shown as fold changes 
normalized to control DCs. (c) DC capacity to induce T cell proliferation was determined by flow 
cytometry. The stimulation index represents the number of cells proliferating in response to 
stimulation divided by number of cells undergoing background proliferation in un-stimulated condition. 
Student’s t-test analysis (control vs tumor-associated DCs; culture with vs without antibodies), *p<0.1 
and **p<0.05 are considered significant. 
 











The CD14 expression level of tumor-associated mDCs showed no alteration compared 
with the control DCs (MFI: 12.90±3.96 vs 9.44±3.15). Addition of antibody against IL-10 or 
TGF- did not alter the CD14 expression level on the tumor-associated mDCs (MFI: 
12.00±3.97 and 11.59±2.59, respectively) (Fig. 23a). In contrast, the HLA-DR expression 
level was significantly enhanced on tumor-associated mDCs (fold change: 1.30±0.37). 
Addition of antibody against IL-10 and TGF- did not change the expression level of HLA-
DR of the tumor-associated mDCs (fold change: 1.35±0.37 and 1.44±0.37, respectively) 
Fig. 23. Immunesuppressive cytokine effect on tumor-associated mDC. iDCs (105 cells/well) were 
generated. On day 5, cytokine cocktail (IL-1, IL-6, TNF-a) along with tumor cells (1:5) were added in a 
transwell system in the absence or presence of IL-10 (5 µg/ml) or TGF- (10 µg/ml). DCs were 
further co-cultured with allogenic CD4 T cells 5 days. (a) CD14 (b) HLA-DR and CD83 expression level 
were calculated by flow cytometry. Measurements were gated on CD11c. (c) DC capacity to induce 
CD4 T cell proliferation was shown by a stimulation index. The stimulation index represents the 
number of cells proliferating in response to stimulation divided by number of cells undergoing 
background proliferation in un-stimulated condition. Results are shown as fold changes normalized 
to control DCs. Data are shown as mean values ± SD of 4 donors. Student’s t-test analysis (control vs 
tumor-associated DCs; culture with vs without antibodies), *p<0.1 and **p<0.05 were considered 
significant. 
 




compared with the tumor-associated mDCs cultured without antibodies. The CD83 expression 
level was enhanced on tumor-associated mDCs (fold change: 1.58±0.82) compared with the 
control DCs. Addition of antibody against IL-10 did not make any significant changes to the 
CD83 expression level on tumor-associated mDCs (fold change: 1.74±0.94) but the addition 
of antibody against TGF- increased the CD83 expression level on tumor-associated mDCs 
(fold change: 1.80±0.84) compared with the tumor-associated mDCs cultured without 
antibodies (Fig. 23b).  
The capacity to induce CD4 T cells proliferation was shown to be not significantly 
different between control DCs and tumor-associated mDCs (SI fold change: 1.27±0.46). 
However, antibody against IL-10 and TGF- increased the capacity of tumor-associated 
mDCs to induce CD4 T cell proliferation (SI fold change: 1.48±0.44 and 1.43±0.54, 
respectively) (Fig. 23c). 
 
3.3.5. Modulation of DCs by exogenous IL-10 and TGF-  
Since the results of this study contradicting the studies emphasizing the importance of 
IL-10 in modulating DCs, exogenous IL-10 and TGF-were added into the culture during the 
DC generation. To investigate the effect of the cytokines on DC differentiation, monocytes 
were cultured in medium supplied with different concentration of exogenous IL-10 (0.2, 2 and 
20 ng/ml) or TGF- (0.5, 1 and 5 ng/ml) for 7 days.  To study the effect these cytokines on 
DC maturation, iDCs were generated for 5 days and then at day 5, cytokine cocktail (IL-1, IL-
6, TNF-) and different concentration of IL-10 (0.2, 2 and 20 ng/ml) or TGF- (0.5, 1 and 5 
ng/ml) were added. The DCs were then phenotypically characterized by flow cytometry and 
further co-cultured with allogenic CD4 T cells to investigate the DC capacity to stimulate T 
cell proliferation.  
The percentage of CD14+ cells of iDCs generated in 0.2 ng/ml IL-10 were similar to 
control iDCs (1.20±0.46 vs 1.11±0.69). The percentage of CD14+ cells increased slightly 
when iDCs differentiated in 2 ng/ml IL-10 (5.89±7.66) but enhanced  significantly in 20 
ng/ml IL-10 culture (22.02±5.49) (Fig 24a). When IL-10 was added during the DC 
maturation, CD14 expression level was not altered (Fig. 24b). The expression level of CD83, 
CD86 and HLA-DR on DCs induced into maturation in the presence of 0.2 and 2 ng/ml IL-10 
were similar with control DCs. In contrast, the expression of CD86 was only 50% of the 
control level (MFI: 39.08±5.68 vs 70.57±31.09, the HLA-DR expression decreased to 75% 




(MFI: 31.94±3.25 vs 44.81±8.04) and the CD83 expression level decreased to 84% (MFI: 
10.73±0.46 vs 12.85±0.83) when 20 ng/ml IL-10 was added into the culture (Fig. 24c). 
The capacity of iDCs to induce CD4 T cell proliferation did not change when 0.2 and 
2 ng/ml IL-10 was added into culture but a decreased capacity (SI fold change: 0.73±.0.07) 
was observed when 20 ng/ml IL-10 was added into culture during DC differentiation (Fig. 
22d). There was no change on DC capacity to induce CD4 T cell proliferation when IL-10 








Fig 24. Effect of exogenous IL-10 on DC differentiation and maturation. (a) Monocytes were 
cultured in the absence or presence of different concentration of IL-10 (0.2, 2 and 20 ng/ml) for 
7 days. CD14+ cells were calculated by flow cytometry (b) iDCs were generated for 5 days, IL-10 
(0.2, 2 and 20 ng/ml) was added on day 5 along with cytokine cocktail (IL-1, IL-6, TNF-). CD14, 
CD86, HLA-DR and CD83 expression level were calculated by flow cytometry. (d-e) DCs were 
further co-cultured with allogenic CD4 T cells for 5 days. Results are shown as stimulation index 
fold changes normalized to the control DC. The stimulation index represents the number of cells 
proliferating in response to stimulation divided by number of cells undergoing background 
proliferation in un-stimulated condition. Data are shown as mean values ± SD of 3 donors. 
Student’s t-test analysis (control vs DCs cultured in different concentration of IL-10), **p<0.05 is 
considered significant. 
 




Addition of exogenous TGF- into culture during DC differentiation, as well as during 
DC maturation, did not change the CD14 expression level of iDCs or DCs (Fig. 25a and b). 
The changes was observed though on the HLA-DR expression level, where addition of 0.5 
ng/ml TGF- into the culture during DC maturation showed a two-fold decrease compared 
with the control (MFI: 14.54 vs 27.07). The decrease of HLA-DR expression was not dose-
dependent as addition of a higher concentration of TGF- (1 and 5 ng/ml) did not decrease the 
expression further (MFI: 15.18 and 12.65, respectively). Similar observation were made for 
the CD86 expression level, where addition of 0.5 ng/ml TGF- was enough to cause a two-
fold decrease compared with the control (MFI: 13.64 vs 25.61). Addition of 1 and 5 ng/ml 
TGF- into culture during the DC maturation also showed a two-fold reduced expression 
level of the CD86 compared with the control (MFI: 14.08 and 13.97, respectively). The 
expression of CD83 showed a decrease level when 0.5, 1 and 5 ng/ml TGF- was added into 
the culture (MFI: 8.27, 7.94 and 8.42, respectively) compared with control DCs (MFI: 9.55) 
(Fig. 25c). 
iDC capacity to induce CD4 T cell proliferation increased when TGF- was added 
into culture, where 0.5 ng/ml TGF- could increase the capacity 1.28 times, 1 ng/ml TGF- 
1.18 times and 5 ng/ml of TGF- 1.70 times compared with control iDCs (Fig. 25d). The DC 
capacity to induce CD4 T cell proliferation also increased when TGF- was added into the 
culture during DC maturation. The addition of 0.5 ng/ml TGF- increased the capacity 1.29 
times, 1 ng/ml TGF- 1.47 times and 5 ng/ml of TGF- 1.48 times compared with control 
DCs (Fig. 25e). 

















Fig 25. Effect of exogenous TGF- on DC differentiation and maturation. (a) Monocytes were 
cultured in the absence or presence of different concentration of TGF- (0.5, 1 and 5 ng/ml) for 
7 days. (b) iDCs were generated for 5 days, TGF- (0.5, 1 and 5 ng/ml) was added on day 5 along 
with the cytokine cocktail (IL-1, IL-6, TNF-). DCs were further co-cultured with allogenic CD4 T 
cells for 5 days. Data of activation and maturation markers are shown as fold changes 
normalized to control DCs. The stimulation index represents the number of cells proliferating in 
response to a stimulation divided by number of cells undergoing background proliferation in an 
un-stimulated condition. Stimulation index is shown as a fold change normalized to control iDCs 
or DCs. Results are shown as a mean value of 2 donors.  
 




3.3.6. Co-inhibitory molecules on tumor-associated DCs 
In addition to immunosuppressive cytokines, expressions of the co-inhibitory 
molecules PD-L1 on DCs were measured on DCs generated in cultures contained melanoma 
supernatant. To investigate the expression of PD-L1 during the DC differentiation, monocytes 
(1x105 cells/well) were cultured in medium only or medium containing 10% or 50% 
melanoma supernatant for 5 days and then expression of PD-L1 was measured by flow 
cytometry. To investigate the changes of PD-L1 expressions during DC maturation, iDCs 
(1x105 cells/well) were generated and then induced into maturation by a cytokine cocktail (IL-
1, IL-6, TNF-) addition in medium only or medium containing 10% and 50% melanoma 











PD-L1 expression level increased when iDCs were generated in the medium containing 
10% tumor supernatant (MFI: 17.75±7.93) compared with the control (MFI: 10.26±3.42). 
iDCs cultured in the medium containing 50% of tumor supernatant showed a significant 
three-fold increase of the PD-L1 expression level (MFI: 34.86±21.82) compared with the 
control (Fig. 25a). PD-L1 expression levels did not differ when DCs were induced into 
maturation in the medium containing 10% or 50% tumor supernatant (MFI: 37.37±13.18 and 
35.62±8.76, respectively) compared with the control (MFI: 35.66±10.55) (Fig. 26b). 
  




3.4. Results summary 
In situ experiments showed: 
 No correlation between IL-10 and TGF- productions, their receptors and responsive 
genes expressions, with the failure of immune response to eradicate melanoma cells. 
T cell anergy model demonstrated: 
 Anergic T cells could be induced in vitro by co-culturing T cells with an equal number 
of tumor cells (ChaMel84).  
 No co-linearity between IL-10 and TGF- productions and anergic T cell induced in 
vitro. 
 Addition of exogenous IL-10 to T cells co-cultured with a low number of tumor cells 
led to a slightly reduced T cell responses (shown by slightly reduced Granzyme B 
production and cell proliferation) capacity upon re-challenged compared with the 
control group. 
 Blocking the endogenous IL-10 did not make any differences to T cell responses upon 
re-challenge in both functional and anergic T cells induced in vitro compared with the 
control group. 
 T cell responses upon re-challenge were better compared with the control when 
exogenous IL-10 was added into T cells co-cultured with an equal number of tumor 
cells.  
 Addition of exogenous TGF-to the anergic or functional T cell cultures caused better 
T cell responses upon re-challenge compared with the control. 
 Blocking the endogenous TGF- made no significant changes in T cell responses upon 
re-challenged in both functional and anergic T cell cultures compared with the control. 
 Better T cell responses upon re-challenge were observed when a combination of IL-10 
and TGF- was applied than using either IL-10 or TGF- alone. 
Tumor associated DCs in vitro showed: 
 Tumor-associated iDCs were a mixed population of cells (consisted of round cells and 
macrophage-like cells), less efficient in inducing CD4 T cell proliferation and 
produced more IL-10 compared with the control iDCs. 
 No correlation between the amount of IL-10 produced by tumor-associated iDCs and 
their reduced capacity to induce T cell proliferation. 




 Blocking IL-10 during tumor-associated iDC generation did not change their capacity 
to induce CD4 T cell proliferation. 
 Tumor-associated mDCs were more activated and had a similar or even an enhanced 
capacity to induce CD4 T cell proliferation.  
 Tumor-associated iDC and mDC cultures in transwell assays showed a reduced TGF- 
production. 
 Only tumor-associated iDCs and mDCs co-cultured with a high number of tumor cells 
in direct contact assays showed a higher TGF- production compared with the control. 
 Endogenous TGF- did not reduce tumor-associated mDC capacity to induce CD4 T 
cell proliferation. 
 Exogenous TGF- addition during DC differentiation did not suppress the DC 
function, instead an enhanced capacity could be observed. 
 Tumor-associated iDCs generated in the transwell assay could still be induced into 
maturation and the resulting matured DCs had similar capacity to stimulate CD4 T cell 
proliferation with the control DCs, in contrast to the tumor-associated iDCs 
differentiated in direct contact assays where maturation was failed to induce and 
consequently, had less capacity to induce CD4 T cell proliferation. 
  





IL-10 and TGF- are suggested to actively suppress anti-tumor immune responses and 
thereby facilitating tumor growth and development since a high expression of IL-10 and TGF-
 was found in varieties of cancers (Kim et al, 1995; Leivonen and Kahari, 2007). The IL-10 
expression was reported in melanoma samples but not in adjacent healthy skin of patients. 
Moreover, serum IL-10 level of advanced melanoma patients was higher than normal 
volunteers (Krüger-Krasagakes et al, 1994; Nemunaitis et al, 2001). All this data led to an 
interpretation of an upregulation of the immunosuppressive cytokines in tumor cases to 
actively suppress the immune system. Contrary to this suggestion, based on in situ results 
from this study, there is no correlation between IL-10 and TGF- production and the failure 
of the immune response to eradicate melanoma cells. Furthermore, no active suppression of T 
cells or DCs functions in vitro by IL-10 and TGF- produced endogenously in culture was 
found.  
Krüger-Krasagakes and colleagues (1994), as well as Itakura and colleagues (2011), 
have studied IL-10 expression in melanoma samples. However, they did not compare 
melanoma with the skin of healthy individuals. Here for the first time, IL-10 and TGF- 
expressions, together with their receptors and responsive genes, were analysed in both 
melanoma and the skin of healthy individuals. The results demonstrated that while the 
expression of both immunosuppressive cytokines to be still detectable in melanoma but the 
expressions were significantly lower in melanoma samples than in the healthy skin samples. 
Likewise, the expression levels of IL-10 receptor and TGF- receptor in melanoma were 
lower than in the healthy skin although the p values > 0.05, indicating a larger variation in 
both sample groups. Despite the observation, lower expression levels in the responsive genes 
of the two cytokines in melanoma and the highly significant difference compared to the 
healthy skin is strong evidence against the active role of these two immunosuppressive 
cytokines in preventing effective anti-tumor immune responses in melanoma. 
This conclusion also hold true for the one melanoma case (ChaMel45) that had a 
higher level of IL-10 expression than the healthy skin (mean value: 73.98 vs 64.56). Here, the 
SOCS-3 expression, as the responsive gene marker for the IL-10 signaling, was still very low 
compared with the mean value in the healthy skin (mean value: 7.61 vs 18.47), indicating a 
low response to the IL-10 induction in this melanoma sample, which is in line with the low 
expression of IL-10R in this sample compared with the healthy skin samples (mean value: 




48.74 vs 100.67). Similarly, in two melanoma cases (ChaMel57 and ChaMel109) where 
higher levels of TGF-expression were found compared with the healthy skin (mean value: 
66.15 and 54.84 vs 27.47), the TGF-R expression levels were lower compared with the 
healthy skin (mean value: 3.47 and 0.80 vs 7.05). As a result, a lower expression of SMAD-7, 
a responsive gene of the TGF- signaling, in these two melanoma samples in comparison with 
the healthy skin (mean value: 1.85 and 6.01 vs 13.18) was observed. 
Thus, IL-10 and TGF- were not upregulated in melanoma samples and even in the 
cases of high expressions of immunosuppressive cytokines, no upregulation of the 
corresponding receptors was observed. Consistently, the cytokine and cytokine receptors 
expressions translated into a low level to no signal transduction as indicated by the low 
expressions of SOCS-3 and SMAD-7 as the responsive gene markers for IL-10 and TGF- 
respectively. It can therefore be concluded that these two immunosuppressive cytokines are 
not important for melanoma development and progression. 
In the in vitro model, anergic T cells, which were un-responsive to tumor re-challenge 
due to the over-stimulation by tumor cells, could be generated. When anergic T cells were re-
challenged, all parameters of T cell responses (T cell proliferation, Granzyme B and IFN- 
production) were low. However, no enhancement of IL-10 or TGF- production was observed 
in the anergic T cell cultures compared with the functional T cell cultures. Thus, there was no 
correlation between T cell anergy and IL-10 or TGF- production. On the contrary, anergic T 
cells seemed to be more activated, shown by the increased expression of CD25 and CD69 
activation markers and enhanced IFN- production compared with the control, leading to a 
conclusion that there was no active suppression by IL-10 or TGF-in the anergic T cell 
model  
Previous studies reported that chronic immune activation, such as happen during 
chronic HIV-infection, is characterized by an increased expression of activation markers of T 
cells and an enhanced pro-inflammatory cytokines production (Haas et al, 2011). These 
reports matched the own observation of enhanced IFN- production and activation markers 
(CD25 and CD69) expression levels by anergic T cells relative to the control. Kinetics 
experiments also supported the idea as an enhanced production of IFN- indicating the 
increasing activation, during the anergy induction showed a positive correlation with the 
number of tumor cells added into the T cell culture.  In tumor, as in persistent virus 
inflammation and autoimmune disease, which all are associated with a chronic inflammation, 




impaired T cell function was reported (Baniyash M, 2004).  The activation state of anergic T 
cells in the in vitro model was in line with the finding of previous study in the group. Analysis 
of TILs from 148 melanoma patients had shown that 80% of tumor-infiltrating T cells were 
memory T cells and about 55% expressed CD69, suggesting a continuous active response 
against the tumor. Similarly, T cells in the in vitro anergic T cell model were mostly memory 
T cells. In previous studies in the group, the active T cells state among TILs was also 
indicated by the expressions of PD-1 and CTLA-4, where about 20% expressed CTLA-4 and 
35% expressed PD-1. The expressions of PD-1 and CTLA-4 could not be detected in anergic 
T cells in the in vitro model though. However PD-1 expression was also different in tumor 
site and peripheral blood, which is in line with the tissue specific differences in PD-1 and PD-
L1 expressions reported by Blackburn (Blackburn et al, 2010). This could explain the 
differences between TILs and anergic T cells which were generated from T cells isolated from 
peripheral blood. Observations from in vitro anergic T cell model and analyses of TILs from 
melanoma patients suggest that anergic T cells are in an active state instead of a suppressed 
state.  
Several experimental studies aim to induce effector T cells against melanoma. A study 
using a trivalent vaccine against self-melanoma antigen glycoprotein 100 (gp100), tyrosinase 
and melanoma antigen recognized by T cells 1 (MART-1) were done to increase T cell 
activity against melanoma (Ingraffea, 2013). As the data from the present and earlier studies 
in the group implicate an active state of TIL and anergic T cells induced in vitro, strategies for 
melanoma therapy that aim at inducing T cell activation need to be reconsidered. 
Recent reports suggesting the importance of IL-10 in monocytes or macrophages 
functions, and therefore further experiments using monocytes and DCs co-cultured with 
tumor cells were carried out. The experiments showed that tumor-associated iDCs were a 
mixed population of cells, consisted of round cells and macrophage-like cells, had a reduced 
DC capacity to induce T cell proliferation, and an enhanced IL-10 production. But again there 
was no correlation between the amount of IL-10 produced by tumor-associated iDCs with 
their reduced capacity to induce CD4 T cell proliferation. Although tumor-associated iDCs 
cultured with a high excess of tumor cells produced around twice as much IL-10 than the 
tumor-associated iDCs cultured with an equal numbers of tumor cells, the capacity of tumor-
associated iDCs in these two groups to induce CD4 T cell proliferation was similar. Blocking 
IL-10 during tumor-associated iDCs generation also did not change their capacity to induce 
CD4 T cell proliferation. IL-10 production by tumor-associated mDCs also increased around 




sevenfold compared with the control DCs but the capacity of tumor-associated mDCs to 
stimulate CD4 T cell proliferation was not suppressed, rather an enhanced capacity up to 30% 
was observed.  
One study supporting the idea of IL-10 mediated immune suppression showed that 
exogenous IL-10 could inhibit DC function (Allavena et al, 1998), however the concentration 
of IL-10 added to the culture was very high (20 ng/ml). A high concentration of IL-10 could 
indeed inhibit DC function as confirmed by the in vitro experiment in this study, however a 
low concentration of exogenous IL-10 alone, which was similar to the endogenous IL-10 
produced by tumor-associated iDCs could not inhibit DC function. These results showed that 
DC modulation by IL-10 was dependent on the IL-10 concentration and earlier studies had 
exceeded by far the naturally induced level.  
Both iDCs and tumor cells used in this study (ChaMel84) did not produce IL-10 when 
cultured alone. However, when cultured together, tumor cells produced IL-10, suggesting that 
an interaction between tumor cells and iDCs was needed to induce the IL-10 production. The 
necessity of cell-cell interaction was confirmed by the results of experiments with tumor 
supernatant. In these experiment, IL-10 produced by DCs generated in the medium alone or in 
the medium containing tumor supernatant was similar even when increasing amount of tumor 
supernatant was used, indicating that cell-cell contact was needed. This result also implied 
that the enhancement of IL-10 production found in the tumor-associated iDCs culture was a 
direct consequence of increasing number of tumor cells used in the culture.  
All this evidence demonstrates that even though IL-10 could be detected in the culture 
of tumor-associated DCs, there was no correlation between IL-10 endogenous production and 
the altered DC phenotype and capacity to stimulate CD4 T cell proliferation. This result 
implies that while DCs altered by tumors may still be important for mediating tumors escape, 
IL-10 production is not important for modulating DCs. Although IL-10 does not seem to be 
involved in altering DCs phenotypes and functions, IL-10 could mediate other mechanisms. 
An in vivo renal carcinoma study showed that IL-10 is able to promote M2 polarization of 
Tumor associated macrophages, a subset of macrophages that have poor antigen-presenting 
capacity and supress T cell activity (Lee et al, 2013). Further studies to investigate the role of 
IL-10 in macrophage polarization are therefore of interest. 
TGF- produced in the tumor-associated DC culture did not translate to an active 
immune suppression. Interestingly, tumor-associated iDC and mDC cultures in transwell 




assays showed a reduced TGF- production. The increase tumor-associated DC capacity in 
inducing CD4 T cell proliferation could be explained by this finding. Blocking TGF- during 
tumor-associated mDC maturation further increased the capacity of tumor-associated mDCs 
to stimulate CD4 T cell proliferation. Exogenous TGF- addition during DC differentiation 
also did not suppress the DC function, instead an enhanced capacity could be observed. 
Similar results were observed when exogenous TGF- was added during DC maturation, 
where the DC function was enhanced although the expressions of activation and maturation 
markers were reduced. DC modulation by TGF- was concentration dependent and an 
increasing TGF- concentration led to an increased DC capacity.  
IL-10 and TGF- were shown to be expressed in tumor with conflicting results 
supporting the role of these cytokines in both immune suppressive and immune stimulation. 
Active suppression of immune responses by IL-10 and TGF- could not be demonstrated in 
this study, leading to the questions about the role of these two cytokines in anergy induction.  
Addition of exogenous IL-10 to T cells co-cultured with a low excess of tumor cells 
seemed to lead to reduced T cell responses capacities upon re-challenged, whereas blocking 
the endogenous IL-10 during the anergy induction did not make any differences in all ratios 
of T cells to tumor cells tested when compared with the control groups. Exogenous IL-10 
seemed to assist the induction of anergic T cells when IL-10 was added into the functional T 
cell culture but the effect was not strong even when a high concentration was applied. Only 
around a 20% reduction of T cell proliferation and Granzyme B production along with no 
reduction of IFN- production were observed. These results could explain why blocking the 
endogenous IL-10 did not have any effect since the endogenous IL-10 production was far 
below the concentration of exogenous IL-10 added into the culture. The opposite effect of 
exogenous IL-10 was observed when IL-10 was added during anergy induction. Here, IL-10 
seemed to interfere with anergy induction as the T cell responses were better when exogenous 
IL-10 was added into the culture.  
The addition of TGF- did not drive T cells to anergy. On the contrary, TGF-
enhanced the capacity of T cells to respond to tumor re-challenged. These experiments also 
showed that adding TGF-during anergy induction did not support the anergy induction 
process nor further suppressed T cell responses since no changes of T cell responses were 
detected, suggesting that exogenous TGF- did not interfere with anergy induction. Blocking 
endogenous TGF- caused no significant changes on T cell responses upon re-challenged, 




indicating that the low concentration of endogenous TGF- was not important for inducing T 
cell anergy. 
As mentioned above, anergic T cells seemed to be in an active state. Kinetics 
experiment showed increasing activity when larger numbers of tumor cells were added into 
the culture, suggested an over-activation state of the T cells when co-cultured with high 
numbers of tumor cells. Exogenous TGF- may protect T cells from over-activation, 
indicated by the low production of IFN- during anergy induction, preserving the capacity of 
T cells for responses upon re-challenged. This proposal is in agreement with a study showing 
a reduced TGF-1 and TGF- receptor expressions in patients with chronic dermatitis 
compared with normal skin which may lead to the retention of inflammation and chronic skin 
inflammation (Khaheshi et al, 2011).  
Combining exogenous IL-10 and TGF- in T cells co-cultured with tumor cells during 
anergy induction seemed to weaken the effect of TGF- to suppress the over-activation of T 
cells as IFN- production during the anergy induction was higher compared with the effect of 
using TGF- alone. Unexpectedly, IFN- production, but not T cell proliferation, was higher 
upon re-challenge when combined cytokines were applied instead of using TGF- alone. 
These results suggest that combining these two cytokines could rescue the anergic T cells to 
some extent. When the combination of IL-10 and TGF- was added into the functional T cell 
culture, better T cell responses were observed upon re-challenge compared with adding either 
IL-10 or TGF- alone, suggesting that TGF- could counter the IL-10 effect in promoting 
anergy. These data implied that TGF- did not actively suppress T cell responses. On the 
contrary, it could interfere with the T cell anergy induction. 
With the in vitro model for anergy induction, pleiotropic effects of IL-10 and TGF- 
could be demonstrated in both immune stimulation and suppression.  IL-10 and TGF- were 
shown to function differently depending on types and different stages of target cells. The 
results urge not to simply categorize these cytokines as targets of anti-immune escape 
therapies. On the contrary, TGF- application to interfere with T cells anergy may add a new 
aspect to the development of immune therapies against cancer. 
The in vitro experiments showed decreased responses of anergic T cells upon re-
challenge but there was no evidence for negative regulation by the immunosuppressive 
cytokines IL-10 and TGF- or the co-inhibitor molecules PD-1 and CTLA-4 in causing this 




impair T cell function. Another possible explanation was offered by in vivo experimental 
demonstrating a downregulation of TCR-zeta chain and an induced impaired T cell function 
upon excessive inflammation (Baniyash M, 2004). An earlier study in melanoma had already 
shown a decrease of TCR-zeta and tyrosine kinases relating to TCR signaling (Zea et al, 
1995). 
The generation of tumor-associated iDCs in vitro showed that tumor cells altered the 
differentiation of monocytes into iDCs. The alteration was more apparent in direct contact 
assay, shown by the higher CD14 expression and the lower DC capacity to stimulate T cell 
proliferation, compared with the transwell assays. However, alteration of iDCs could still be 
observed in the transwell assay, suggesting that tumor-derived molecules or tumor-induced 
soluble factors impact DC differentiation.  
Exosomes are membranous particles released from cells. They can contain a variety of 
molecules, including peptides, mRNA, microRNA, lipids. Exosomes have been described as 
an alternative pathway used by tumor cells to suppress immune system (Zhang and Grizzle, 
2011). Exosomes could be exempted in this study since exosomes-free medium used to 
differentiate monocytes was still able to alter DCs. This experiment also showed that DC 
alteration was dose dependent since alteration was more extensive when higher 
concentrations of the tumor supernatant were used in the experiments.  
 In transwell assays, tumor-associated DCs generated in the absence of activation 
signal (inflammatory cytokines) had a lower capacity to stimulate CD4 T cells compared with 
the control iDCs. However, in the presence of activation signal, the capacity of tumor-
associated DCs was similar to control DCs. This result is in line with the concept that the DC 
system is in flux and dependent on inflammatory reaction (reviewed by Shortman and Naik, 
2007). However, when tumor-associated DCs were generated in direct contact with tumor 
cells, the presence of activation signal did not induce the maturation of altered iDCs (CD83 
expression remained low) and the capacity to stimulate CD4 T cells was reduced. This result 
suggested that although tumor-derived soluble factors can modulate DC phenotypes and their 
capacity to stimulate T cell proliferation, a direct contact with tumor cells was needed to 
completely determine the alteration of DCs.  
In contrast to the effect of tumor cells during DC differentiation, tumor cells do not 
seem to have a negative effect on DC maturation or activation. In transwell assays, tumor-
associated mDCs even had an increased activation and enhanced capacity to induce T cell 




proliferation. IL-10 production also increased in the tumor-associated mDC culture, 
suggesting that IL-10 production may thus be used as an indicator of activation. This idea was 
also supported by the results demonstrating that mature DCs produced IL-10 but immature 
DCs did not.  
To answer whether tumor cells alone are sufficient to induce DC maturation, iDCs 
were generated and tumor cells were added. The results showed low expressions of activation 
markers and low capacity to induce CD4 proliferation, indicating that tumor cells alone are 
insufficient to induce DC maturation. This result is in line with studies done by Joffre and 
colleagues (Joffre et al, 2008), which showed that tissue-derived signals are not sufficient to 
activate DCs in chimeric mice. The experiments in this study also showed that tumor-
associated iDCs were more activated than control iDCs but the capacity to induce T cell 
proliferation remained low. The results were in agreement with previous reports showing that 
DC activation could be tolerogenic as iDCs co-cultured with tumor supernatant displayed 
enhanced activation markers but had a decreased capacity to stimulate CD4 T cells 
(Kiertscher et al, 2000). 
Baumgartner and colleagues found that DC maturation and function are not altered by 
melanoma-derived immunosuppressive soluble factors (Baumgartner et al, 2012).  The 
difference of results could relate to the use of LPS by Baumgartner and colleagues to induce 
DC maturation. LPS is a strong stimulant and probably the effect is too strong so that the 
difference between groups could not be detected. That was the rational for using a cytokine 
cocktail to induce DC maturation in this study as the cytokine cocktail is a far weaker 
stimulant than LPS.  
IL-10 and TGF-productions were shown to have no correlation with the DC 
alteration in this study although tumor-associated iDC culture produced IL-10. Aside from IL-
10 and TGF-, other soluble factors have been suggested in different studies to be able to 
modulate immune response. DNA chip analysis of ChaMel84, which was used in this study, 
had been done before and had shown upregulation relative to melanocytes of some soluble 
factors that were correlated with a tumor progression. ChaMel84 expressed 23 times 
upregulation of IL-8 compared with melanocytes. Neutralizing IL-8 is shown to inhibit 
angiogenesis, tumor growth and metastasis of human melanoma in nude mice (Huang et al, 
2002). It also expressed 12 times more of CXCL16 relative to melanocytes. Increasing 
CXCL16 is correlated with poor prognosis in colorectal cancer (Verbeke et al, 2011) and it 
seems to be important in the bladder cancer progression (Lee et al, 2013). A seven-fold 




increase of IL-33 expression was also found in ChaMel84 compared with melanocytes. 
Increased level of IL-33 is correlated with poor prognosis in gastric cancer (Sun et al, 2011). 
The mechanism by which these cytokines modulate immune responses and support tumor 
progression is still unknown. The correlation between these cytokines and DC modulation or 
immune modulation in general, is an important aspect to be explored.  
Since a negative regulation of immune response by immunosuppressive cytokines 
could not be found, a negative regulation by co-inhibitor molecules was investigated as well. 
A dose-dependent increased expression of PD-L1 was detected when iDCs were generated in 
the presence of tumor supernatant. This could explain the decreased tumor-associated iDC 
capacity to induce T cell activation. This result supported the idea of addressing the PD-1/PD-
L1 axis in the cancer therapy. Clinical trials evaluating the anti PD-L1 in cancer treatments 
are still on going. However several open issues are still unresolved, such as: the heterogeneity 
of PD-L1 expression and the prognostic role of TILs in addition to PD-1/PD-L1 to identify 
patients who will be benefit from such therapy (Merelli et al, 2013).  
In addition to the PD-1/PD-L1 axis, a treatment to apply antibodies against CTLA-4 is 
also interesting to pursue as an increased CTLA-4 expression was observed in melanoma in 
previous studies in the group, as well in cancer tissue of non-small-cell-lung cancer patients 
compared with healthy individual (Antczak et al, 2013). One study showed that dual blocking 
of PD-1 and CTLA-4 leads to a reversal of dysfunctional TILs and to tumor rejection in a 
mice model for carcinoma (Duraiswamy et al, 2013). Ipilimumab, an antibody targeting 
cytotoxic T cells, was approved by FDA in 2011 to be applied against un-resectable 
melanoma. Blockage of CTLA-4 can lead to durable cancer regression and phase III studies 
show a survival benefit for melanoma patients. However, ipilimumab can lead to immune-
related adverse events, which can be serious and life threatening (Frederick et al, 2013, 
Ingraffea, 2013; Callahan et al, 2013; Tarhini, 2013; Finn et al, 2012). 
DCs are shown to play an important role in anti-tumor responses as it has been 
reported that tumors infiltrated by DCs are associated with a good prognosis. On the contrary, 
some reports also conclude that DCs can exert pro-tumorigenic functions by blocking the 
anti-tumor responses and support angiogenesis and metastasis (reviewed in Ma et al, 2013). 
Experiments done in mice shows DCs in early tumorigenesis are immunocompetent while 
DCs in the late stages are immunosuppressive (Scarlett et al, 2012). The in vitro model 
developed in this study showed that DCs co-cultured with tumor cells indeed response 
differently in different stages and the changes were related to the tumor burden, resembling 




the changes of DCs during the tumor progression. Exposure of tumor cells during DC 
differentiation would alter DC phenotypes and render DC capacity to induce CD4 T cell 
proliferation in line with the tumor burden. On the contrary, exposure to tumor cells had no 
negative effect on DC maturation and could even enhance the activation of DCs. This in vitro 
model provided a mean to study the effect of tumor cells on DCs and observe what tumor 
cells do or do not do to DCs. The study of DC modulation by tumors is important as DCs are 
the main APCs to present tumor-associated antigens to T cells. DC-based tumor vaccines 
have been extensively tested but the results of the respective clinical trials were mostly 
disappointing. Many explanations have been offered for the ineffectiveness of DC-based 
tumor vaccines, including inefficient antigen loading, altered DC maturation states, 
heterogeneous DC populations, and tumor-mediated immune suppression (reviewed in Evel-
Kabler and Chen, 2006). This in vitro model can help to further unravel DC modulation by 
tumors in human.  
Analysis of iDC morphology showed that tumor-associated iDCs were a mixture of 
round-unattached-cells and macrophage-like cells. Flow cytometry analysis showed a mixture 
of CD14- and CD14+ cells in the culture. Since only unattached cells were harvested to be 
analyzed by flow cytometry, the high expression of CD14 on these unattached cells indicating 
the incomplete differentiation from monocytes into iDCs. The DCs modulated by tumor cells 
during their differentiation resembles myeloid-derived suppressor cells (MDSC) described in 
patients with different cancers. MDSCs are described as a population of mixed cells that stay 
in immature state, have myeloid origin and ability to suppress T cell responses. MDSCs are 
found in blood of patients with various cancers (Gabrilovich and Nagaraj, 2009; Simpson et 
al, 2012).  
Aside from MDSCs, iDCs co-cultured with tumor cells in this experiment might also 
fit the model of regulatory dendritic cells. Tumor cells are suggested to be able to differentiate 
iDCs into a subset of DCs, so called regulatory dendritic cells. Tumor-associated regulatory 
dendritic cells are suggested to directly and indirectly maintain antigen specific and non-
specific T cell responses by secreting TGF-, controlling T cell polarization, promoting T-reg 
differentiation and activity, and promoting MDSCs. The expression of immunoregulatory 
molecules (i.e. PD-L1, PD-L2, B7-H3, B7-H4), increased production of immunoregulatory 
cytokines (i.e. IL-10, TGF-), or decreased production of pro-inflammatory cytokines (i.e. IL-
6, IL-12, TNF-) have been described in various regulatory dendritic cell models. In addition, 




tumor-induced regulatory dendritic cells show a reduced expression of MHC class II and the 
co-stimulatory molecules CD80 and CD86 (reviewed in Ma et al, 2012; Shurin et al, 2013). 
The in situ studies showed that not only no upregulation of IL-10 and TGF-was 
detectable, but the expression levels from these two cytokines were also considerably lower 
compared with the expression in the healthy skin. This finding suggests a relatively high 
expression of these cytokines in healthy skin which is not surprising considering skin acts as 
the first barrier against infections. Skin is exposed to microorganisms all the time and it needs 
immunosuppressive mechanism to suppress the excessive immune reaction. These results 
suggest that IL-10 and TGF- are important to suppress the excessive immune reaction in 
healthy skin. This suggestion is also in line with the finding of relatively low expression of 
IL-10 in psoriasis lesions compared with healthy skin (Cheng et al, 2001). Psoriasis is an 
inflammatory disease of skin with a complex pathogenesis. The low expression of IL-10 in 
psoriasis lesions could contribute to the disease progress. High systemic level of IL-10 was 
correlated with poor survival of some cancer patients (reviewed in Mocellin et al, 2005) and 
in connection to the result reported herein, the high level of IL-10 might just reflect the extent 
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 Table 3. Patients and Tumor Status 
 
Patient ID Stage MM 
subtype 
Metastasis location Treatment 
ChaMel44 3 NM SK/ ST/ BO S, C, A 
ChaMel53 3 NM SK/ ST/ BO S, C, A 
ChaMel74 3 NM LU, LI S, C, A 
ChaMel84 3 NM SK/ ST/ BO S 
ChaMel87 3 NM CNS, SK/ ST/ BO S, C, R 
ChaMel96 3 NM LU S, C 
ChaMel41 4 SSM LI, SK/ ST/ BO, CNS S, C, R 
ChaMel21 3 SSM LU, SK/ ST/ BO S, C, A 
ChaMel39 3 SSM LI, SK/ ST/ BO S, C, A 
ChaMel45 3 SSM LU S 
ChaMel47 4 SSM LU, CNS, SK/ ST/ BO S, C 
ChaMel57 3 SSM nd S 
ChaMel60 3 SSM CNS, SK/ ST/ BO S, C 
ChaMel80 3 SSM CNS, SK/ ST/ BO S, C 
ChaMel109 3 SSM SK/ ST/ BO S, C, A 
ChaMel121 4 SSM CNS, SK, ST, BO S 
ChaMel50 3 SSM CNS, SK/ ST/ BO S 
ChaMel59 3 nd LU, SK/ ST/ BO S, C, A 
ChaMel114 3 nd LU S, C 
ChaMel105 3 nd LN, ST S 
ChaMel5 4 nd LU, LI S, C, A 
(extracted from Stefani Gross’ dissertation) 
 
NM : nodular melanoma 
SSM : superficial spreading melanoma 
nd : not described 
 
LU : lung 
LI : liver 
SK : multiple skin metastases 
ST : soft tissue 
BO : bone 
CNS : central neuron system 
 
S : surgery 
C : chemotherapy 
A : adjuvant 
R : radiotherapy  






Hiermit erkläre ich, dass ich die vorliegende Arbeit selbstständig und nur mit den 










Berlin,    Januar 2014 
  







Hiermit erkläre ich, dass ich Kenntnis von der dem angestrebten Verfahren zugrunde 











Berlin,    Januar 2014 
  




List of Publications 
 
In preparation: 
1. IL-10 and TGF- regulation in melanoma. (first author) 
 
 
